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I Motor neuron disease
Motor neuron disease (MND) is characterized by the progressive loss of motor neurons that control 
voluntary muscles. Due to its progressive nature, the muscles gradually lose their function leading 
to paralysis and, ultimately, death. The most common variant of MND is amyotrophic lateral sclerosis 
(ALS). Of all the people diagnosed with ALS, 50% die within approximately two to three years after 
their first symptoms arise and only about 20% live longer than 5 years [1]. Onset is typically around 
50 - 70 years of age, but in some patients the onset may be much earlier, around the age of 
20 - 30 years. Incidence is higher among men than women, estimated at 2:1 [2-4]. The first symptoms 
usually occur in the limbs, but muscle weakness may also begin in the bulbar region. Progressive 
weakness of the respiratory muscles leading to respiratory failure is the most common cause of death. 
Before the first clinical signs of muscle weakness become apparent, more than 50% of the motor 
neurons innervating a muscle may already be lost [5]. In the Netherlands, approximately 1,700 people 
(prevalence 10.3 per 100,000) suffer from ALS [2]. Every year, approximately 500 people (incidence 2.8 
per 100,000) in the Netherlands are diagnosed with ALS [2], and about the same number of persons 
dies every year. In comparison, approximately 570 people in the Netherlands died in traffic accidents in 
2013 [6]. The term ALS was first described in 1874 by Jean-Martin Charcot [7]. Despite the tremendous 
technological progress that has been made in the last 140 years and despite numerous studies that 
have been conducted to unravel the mechanisms that may cause this deadly disease, relatively little 
is known about the mechanisms that cause ALS and the progressive degeneration of motor neurons 
is often unpredictable. The great majority of patients is classified as having sporadic ALS, and only 
5 - 10% of the patients have a familial history of this disease. A complex interaction between genetic 
and environmental factors is believed to contribute to the development of the disease. Several genes 
have been identified and their discovery gave new insights into the underlying pathophysiological 
mechanisms. At present, no cure is available, and the only approved and widely used medication 
(Riluzole) can only marginally slow down the progression of the disease by approximately 3 months [8]. 
 In this section, first the concept of a motor unit as a crucial component being affected by MND 
will be introduced, together with some basics on how motor units are affected in this condition. 
Next, one of the most obvious clinical signs, fasciculations, will be discussed, followed by the varying 
clinical phenotypes. Subsequently, the difficulties in the diagnostic process and the prognosis will be 
described. Currently, both can be very difficult, especially in the early stages of the disease, even with 
a thorough clinical and electrodiagnostic examination.
The motor unit 
In MND, the motor neurons that control voluntary muscle movement are particularly affected. The 
most direct non-invasive measure at the level of single motor neurons is the functioning of motor 
units (MUs) in a nerve-muscle combination with electrophysiological techniques. Therefore, the 
structure and functioning of MUs have a central role in the electrodiagnostic examination. An MU 
is the smallest functional element in the human body that controls skeletal muscles. An MU consists 
of three basic components, an α- motor neuron (lower motor neuron or LMN) in the brainstem or 
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spinal cord, an axon and all the muscle fibers it innervates (Fig. 1). The motor axons from the spinal 
cord innervating the foot muscles can reach lengths of up to 1 meter [9]. Motor axons are bundled in 
fascicles, and a motor nerve is composed of several of these fascicles. The axon of an MU is enclosed 
by a myelin sheath, which covers > 99% of the entire axon [10]. Due to the myelin sheath, the axon 
can transfer action potentials much faster than unmyelinated fibers (a nerve conduction velocity of 
50 - 55 m/sec in the median nerve [11]). At the distal end of the MU, the axon branches into several 
sprouts innervating individual muscle fibers through the neuromuscular junction. Depending on the 
specific function of the muscle, the number of MUs varies widely. In a healthy individual, MU sizes and 
the MU size distribution varies depending on the muscle function: from a few muscle fibers per motor 
unit in muscles exhibiting fine motor control (e.g. extraocular, less than 10 muscle fibers per motor 
unit) to up to a few thousand muscle fibers in leg muscles (e.g. gastrocnemius, 1,000 - 2,000 muscle 
fibers per motor unit) [12].  
  The number of MUs within a muscle can change due to various factors such as age, injury or 
disease. The major pathophysiological change in MND is the progressive loss of MUs, so methods 
that estimate the number of MUs can be used as potential tools to monitor disease progression. The 
loss of MUs leads to the denervation of muscle fibers. These denervated muscle fibers may connect 
to other motor axons of still functioning MUs. This compensatory process is known as reinnervation, 
resulting in clustering of muscle fiber types in a muscle (fiber type grouping). As a result, remaining 
MUs increase in size (more muscle fibers per motor unit), and muscle force can remain more or less 
unaffected for some time, at least in the early phase.  
  To control muscles during voluntary movements, electrical impulses that arise in the upper motor 
neurons (UMN) in the motor cortex are transferred via central motor pathways to the LMN. From there, 
the electrical impulses continue to travel via the axons and the neuromuscular junction, leading to 
controlled activation of MUs, resulting in movement of skeletal muscles. The MUs in a muscle are 
recruited in an orderly manner during voluntary contraction (Henneman’s size principle). However, 
MUs can sometimes show uncontrolled, spontaneous activity, which is known as fasciculations. 
Fasciculations 
Fasciculations are regarded as the most obvious clinical characteristic in ALS. Fasciculations can 
be visible as small, spontaneous, random movements of a muscle when they occur just beneath 
the surface of the skin. The electrophysiological equivalent of a fasciculation is a fasciculation 
potential (FP) that occurs due to spontaneous, isolated, sporadic discharges of an individual MU 
[14]. The identification of this type of ectopic MU activity is an essential part of the electrodiagnostic 
examination as FPs have been included in the latest diagnostic criteria for ALS [15]. They are often 
seen at an early stage of the disease in muscles without weakness [16, 17]. FPs may originate at the 
distal end of the motor axon, along the entire axon, in the cell body or even more central regions [17-
21]. However, FPs are not disease specific and can be observed in various peripheral nervous system 
disorders, and even in healthy subjects [22, 23]. Therefore, FPs as the only abnormality in a muscle is 
insufficient for the diagnosis of ALS and they should be considered in the context of other clinical 
and/or electromyographic (EMG) findings [24, 25]. However, the complete absence of FPs raises 
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clinical doubt in diagnosing patients with ALS [15, 26]. Regarding their prognostic significance, several 
studies have shown mixed results in disease progression and survival [27-29]. From this data, it can be 
said that the importance of fasciculations in ALS is recognized, however there is a lack of fundamental 
understanding of their underlying pathological and non-pathological origins [30].
Clinical phenotypes
Clinical features of ALS include the combined involvement of UMN loss in the motor cortex and/
or degradation of the corticospinal tract, and LMN loss in the brain stem and spinal cord. Clinical 
symptoms of LMN dysfunction include muscle atrophy, muscle weakness and fasciculations. Typical 
clinical symptoms of UMN dysfunction are exaggerated deep tendon reflexes (often in weakened 
muscles), pathological reflexes (Babinski signs) or positive brainstem reflexes, spasticity, and increased 
uncontrolled crying or laughing, as a sign of loss of inhibition. At clinical presentation, patients may 
show large variation in the extent of UMN and LMN involvement.  Main clinical presentations are a) 
limb onset, showing combined UMN and LMN signs in the hands and/or legs, or b) bulbar onset, 
presenting as difficulty with speech, eating and swallowing. A minority of patients with ALS may also 
show mild behavioral or cognitive impairment overlapping with frontotemporal dementia [31, 32]. 
   MND consists of other somewhat rarer conditions, in addition to the most common variant ALS, 
including progressive muscular atrophy (PMA), a clinically pure LMN syndrome [33], primary lateral 
sclerosis (PLS), characterized by pure UMN involvement [34] and progressive bulbar palsy, which solely 
include LMN dysfunction in the bulbar region [35]. PLS and PMA are related to ALS, often regarded 
as positioning at either end of the UMN-LMN spectrum [34, 36, 37]. However, PLS is a much rarer 
variant. In contrary, it is not uncommon that patients initially diagnosed with PMA develop UMN 
signs in a later stage and need to be re-classified as having ALS [38]. PMA is thought to have similar 
pathophysiological effects on the peripheral nervous system as ALS [36, 37]. 
Figure 1. Schematic view of two MUs: The cell body in the spinal cord, the axon in the nerve and the innervation of the 
muscle fibers, via the neuromuscular junction. (Adapted from [13])
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Diagnostic and prognostic challenges
Presently, ALS cannot be diagnosed by a specific screening test or biomarker, which makes the 
diagnostic process a challenging task. Diagnosis of ALS may be difficult as there exist various 
neurological disorders that may resemble the clinical signs of ALS. For instance, in an early stage when 
a patient presents with LMN onset with only focal symptoms, which is comparable to segmental spinal 
muscular atrophy (SMA), often a less severe disorder restricted to a single limb or body region. Some of 
the most common ALS-mimics include, benign fasciculation syndrome (BFS, abundant fasciculations, 
no muscle weakness), multifocal motor neuropathy (MMN, fasciculations, muscle weakness, motor 
nerve conduction block), inclusion body myositis (IBM, weakness predominantly of the flexor muscles 
of the arms, hands and proximal legs, and swallowing difficulties), cervical myeloradiculopathy 
(secondary to degenerative spine disease). It has been shown that approximately 10% of patients 
initially diagnosed as having ALS later turned out to have another disorder [39]. The heterogeneous 
clinical presentation of ALS with symptoms that may also have an overlap with other neuromuscular 
disorders contribute to a diagnostic delay of approximately 12 months [40]. The progressive nature of 
the clinical symptoms and signs in ALS is of importance and ‘time’ is often seen as the most valuable 
diagnostic tool by neurologists as the diagnosis becomes more evident with passage of time [41]. 
 
Diagnostic classification  
An important part in the diagnostic process for ALS is investigating the peripheral nervous 
system using the electrodiagnostic examination, which can be seen as an extension of the clinical 
examination. Depending on the clinical situation, several other additional investigations may be 
performed as well, such as blood tests, muscle biopsy, and neuroimaging (MRI). Electrodiagnostic 
examination can confirm the underlying pathological process in clinically affected muscles but 
more importantly, it may also detect changes in clinically still unaffected areas. Furthermore, it can 
help to rule out other disorders that have a large clinical overlap with ALS [42, 43].    
  For diagnosis, clinicians mostly rely on identifying the widespread presence of LMN and UMN 
abnormalities with progressing of clinical symptoms and exclusion of other disorders that may explain 
the clinical signs. There has been an ongoing debate on the optimal diagnostic criteria for ALS [43], 
and this has led to several changes in the past decades (El Escorial criteria (EEC), revised EEC, and 
Awaji [15, 42, 44]). In these criteria, the body is divided into four regions: cranial, cervical, thoracic and 
lumbosacral based on the origin of nerve roots in the spinal cord or brainstem of the investigated 
muscles. Diagnostic certainty is based on the number of regions involved. In the latest diagnostic 
criteria (Awaji criteria, 2008 [15]) equal weight has been given to detecting LMN abnormalities in a 
muscle using either clinical signs or EMG findings emphasizing the need for clinical neurophysiological 
examination in the diagnostic process of ALS (Fig. 2). 
 Detection of UMN signs is limited to clinical signs only. Furthermore, FPs have been added to the 
diagnostic criteria as an EMG finding of LMN involvement (for detailed EMG criteria, see next section). 
However, their diagnostic status has been criticised as their presence is not specific, but widespread 
fasciculations are characteristic of ALS.  
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Figure 2 (A) Schematic view of the Awaji criteria. Detecting UMN abnormalities is limited to clinical signs only. LMN 
abnormalities can be found with either clinical signs (muscle weakness, atrophy, and/or fasciculations) or EMG signs 
(reinnervation/chronic denervation and active denervation, see next section). (Adapted from [45]) 
Follow-up 
Even after making the diagnosis of ALS, the disease progression varies largely per patient, making 
it difficult for the physician to predict how the disease will progress. To optimally inform patients 
and to improve the clinical process, mitigating these uncertainties is crucial. At present, accurate 
assessment of disease progression is difficult. Therefore, objective measures to assess disease onset 
and progression are necessary not only for an early diagnosis and improved prognostication, but also 
to help with patient selection for therapeutic trials. This will be all the more relevant once effective 
therapies are developed for this fatal disease.
Scope of this thesis
In the electrodiagnostic studies for MND, several EMG techniques are applied, measuring the electrical 
activity arising in a muscle or nerve. The EMG signal of an MU is the summation of all muscle fibers 
that make up the MU, the MU action potential (MUAP). Evaluating the structure and functioning 
of MUs has a central role in these electrodiagnostic studies. Although current EMG techniques, 
including invasive needle EMG and single channel surface EMG, have proven their clinical utility, they 
also have their shortcomings. However, these can partly be resolved using more advanced surface 
EMG techniques by the manner in which MUs are activated and by the use of multiple surface EMG 
channels. These techniques may eventually further assist in improving the diagnostic process and 
lead to a more objective insight into the disease progression. The clinical and pathophysiological 
similarities between ALS and PMA necessitate a similar clinical approach. Therefore, the broad scope of 
this thesis is the non-invasive study of MUs in patients with ALS and PMA using advanced surface EMG 
techniques, further improving their methodology, and assessing their clinical value. This will require 
an understanding of routine EMG techniques, including the way they detect LMN abnormalities, as 
well as insight into the application of more advanced surface EMG techniques. These will be discussed 
in the next section, followed by the specific aims and outline of this thesis. 
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II Basics of EMG techniques in clinical practice
Although Galvani already noted the relation between electrical stimulation of the nerve and the 
contraction of frog limb muscles in 1791, the history of clinical application of EMG is relatively short. 
A lot of progress has been made in the mid-twentieth century. The first International Congress of 
Electromyography was held at the University of Pavia in 1961 where speakers such as Frits Buchthald, 
Eric Kugelberg and Howard Edward Lambert gave famous lectures [46]. Lambert proposed the first 
electrodiagnostic criteria for ALS in that period [47].
Electrodiagnostic studies 
Electrodiagnostic studies consist of two routinely used methods: nerve conduction studies (NCS) 
using non-invasive surface EMG, and invasive needle EMG examination. Abnormalities detected on 
needle EMG have a crucial role in the electrodiagnostic criteria for diagnosing ALS. NCS also have a 
role in ruling out disorders that may resemble ALS. 
A
Normal
C
Myogenic
B
Neurogenic
Figure 3 Schematic view of two MUs in upper graph: (A) in normal condition, (B) in neurogenic condition (MU loss and 
increased MU size) and (C) in myogenic condition (muscle fiber loss and reduced MU size). The signals that might be 
recorded on needle EMG are depicted in the lower graphs: at rest, during slight contraction and maximal contraction. No 
muscle activity at rest in normal conditions (A), some fibrillations, PSWs, or FPs in neurogenic conditions (B) and some 
fibrillations or positive sharp waves in myogenic conditions (C). A few MUAPs and a full interference pattern at slight and 
maximal contraction in normal conditions (A), some giant MUAPs and a reduced interference pattern in neurogenic 
disorders (B), and smaller MUAPs and a full interference pattern with reduced amplitude in myogenic disorders (C). 
(Adapted from Kandel, E., et al. (2013), Principles of Neural Science [48] reproduced with permission of McGraw-Hill 
Education)
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Needle EMG 
Needle EMG is useful in the diagnostic process of neuromuscular disorders to find out which part 
of the MU is affected (Fig. 3). For example, when a patient has muscle weakness, this test can help 
differentiate whether the nerve fibers or the motor neurons are affected (neurogenic weakness) or 
whether the muscle fibers are affected (myogenic weakness). However, needle EMG is an invasive 
method, requiring the insertion of a needle electrode into the muscle under investigation, making it 
also less suitable for repeated examination. 
EMG findings of LMN involvement in a muscle 
In the diagnostic criteria, EMG findings of LMN involvement in a muscle is supported by the presence 
of active denervation and reinnervation (chronic denervation). Active denervation is defined as 
the presence of either positive sharp waves (PSW), fibrillations or FPs (added to the Awaji criteria). 
Fibrillations and PSWs are the spontaneous activity of single muscle fibers due to e.g. denervation, 
where there is no longer a connection between motor axon and muscle fiber. Reinnervation is 
confirmed by enlarged, frequently polyphasic, unstable, long-duration MUAPs, and a reduced 
recruitment pattern. In the lumbosacral and cervical regions, two or more muscles innervated by a 
different spinal root need to be affected to define a body region as being affected. In the thoracic and 
cranial regions, one or more muscles need to be affected. 
  The needle EMG signal is most sensitive to the electrical activity of only a few muscle fibers 
close to the needle tip. Therefore, the needle EMG signal is only an indirect measure of MUAP size. 
Furthermore, even slight movements have an enormous effect on the needle EMG signal, which 
makes quantification of MUAP size difficult. The needle tip is surrounded by muscle fibers belonging 
to only a few MUs. Therefore, the standard procedure is to insert the needle 3 – 5 times at different 
depths and in several different directions to get an accurate impression of how MUs function in a 
muscle. As one can expect, this procedure is uncomfortable and painful. Furthermore, needle EMG 
can be challenging as patients are asked to perform several muscle contractions, which requires a 
patient’s cooperation.
Nerve conduction studies
Nerve conduction studies (NCS) can be divided into motor NCS and sensory NCS. In motor NCS, 
transcutaneous electrical stimuli are applied to activate the motor nerve and a single channel 
EMG signal (derived from a single electrode pair above the muscle) records the electrical activity 
generated in the muscle supplied. In peripheral nervous disorders, several parts of the MU can be 
affected, such as the myelin sheath surrounding the axon, reflected by the motor nerve conduction 
velocity (NCV), or the axon itself, reflected by the amplitude of the compound muscle action 
potential (CMAP). In MND, the myelin sheath generally remains intact and therefore the motor NCV is 
normal. A significantly decreased NCV could suggest an alternative diagnosis such as demyelinating 
(inflammatory) neuropathy. In addition, the presence of focal conduction block, detected by a drop 
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in amplitude between distal and proximal sites of stimulation, would increase the clinical suspicion 
of multifocal motor neuropathy (MMN). In an advanced stage of MND, axonal loss could result in 
a reduced maximum CMAP amplitude, however a large number of axons may be lost before this 
becomes visible as a reduced maximum CMAP amplitude. In sensory NCS, sensory NCV and amplitude 
are evaluated and these are typically normal in patients with MND.
  NCS are non-invasive, so they cause little discomfort for patients. However, it is not possible to 
measure individual muscle fibers, and the identification of single MUs is less accurate than in needle 
EMG. Conventional NCS are therefore not well-suited for assessing single MUs. 
Although needle EMG and NCS have proven clinical utility, they have shortcomings such as the ones 
described above. Surface EMG methods that vary in the electrical stimuli applied to activate MUs 
and that use multiple surface EMG channels can partly resolve these issues and have the potential to 
complement and enhance the two clinically applied methods at the level of single MUs. This will be 
discussed in more detail in the next section. 
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III Advances in surface EMG methods for clinical application
Due to the recent technical advances, significant interest has grown in the use of advanced surface 
EMG techniques for the diagnosis and follow-up of neuromuscular disorders. These techniques may 
reveal electrophysiological characteristics at the level of MUs that cannot be obtained with routine 
EMG techniques and therefore have the potential to be of clinical value. Furthermore, they may be 
able to partly replace or limit the use of painfully invasive and extensive needle EMG examination. In 
devastating diseases such as ALS and PMA, any improvement of diagnostic and prognostic yield as 
well as patient-friendliness of test methods is more than welcome. Research in the department of 
Neurology and Clinical Neurophysiology at the Erasmus MC University Medical Center in Rotterdam 
is at the forefront of these developments. Our focus has been on the development, integration, and 
application of these novel techniques, both in a research setting and in clinical diagnostic practice. 
These sophisticated surface EMG methods include the CMAP scan, motor nerve excitability testing, 
and high-density surface EMG (HDsEMG) recordings. A picture of the complete measurement setup 
is shown in Figure 4.
  Recent progress in the application of these techniques in clinical practice will be described.  Due 
to this progress, it is now possible to identify areas for improvement in the development of these 
techniques as a clinical tool. This thesis attempts to close the most significant of these gaps. 
 
 
 
 
Figure 4. Illustration of the complete measurement setup with the subject positioned on a clinical 
examination bed. It shows the equipment for (1), the HDsEMG recording (PC with sEMG software, 
BioSemi acquisition system), for (2), the CMAP scan recording (Viking Select EMG system), and for (3), 
the motor nerve excitability testing (laptop with Qtrac software, data acquisition system, DS5 Stimulator) 
 
 
 
 
The CMAP scan 
The compound muscle action potential (CMAP) scan is a single channel surface EMG 
method and can be regarded as an extension of standard motor NCS [49]. The CMAP scan 
uses the underlying physiological principle that every MU has a specific threshold for 
activation. When the CMAP amplitude is recorded in response to gradually increasing 
stimulus intensity (SI), all MUs are successively activated. By plotting the CMAP amplitudes 
versus the SI, the characteristic pattern of the CMAP scan becomes visible (Fig. 5). In 
addition, the width of the CMAP scan (lowest to highest MU threshold) gives an indication of 
excitability properties of all activated axons [50].   
  The CMAP scan provides clinical information regarding MU and axonal excitability 
variables that cannot be obtained during routine NCS [49-53]. The CMAP scan has the 
potential to be a valuable tool to monitor disease progression in patients with ALS and PMA 
[54]. MU loss and enlarged MUs due to reinnervation is typical in patients with MND and can 
result in the addition of relatively large MUAPs to the CMAP [51]. This contribution is often 
visible as gaps in the CMAP scan (Fig. 6). Hence, the presence of multiple gaps is indicative 
of MU loss and reinnervation. Currently, a manual procedure is required to identify these 
gaps or so-called steps. In chapter 2 of this thesis, an automated approach is described to 
extract the visual characteristics from the CMAP scan, which has the potential to overcome 
operator-related variability and to reduce time required for the analysis.  
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Figure 4. Illustration of the complete measurement setup with the subject positioned on a clinical examination bed. It 
shows the equipment for (1), the HDsEMG recording (PC with sEMG software, BioSemi acquisition system), for (2), the 
CMAP scan recording (Viking Select EMG system), and for (3), the motor nerve excitability testing (laptop with Qtrac 
software, data acquisition system, DS5 Stimulator)
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Figure 5. The CMAP scan (stimulus-response curve) of a healthy subject showing a gradual increase in CMAP amplitude.     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Figure 6. The CMAP scan (stimulus-response curve) of an ALS patient showing gaps or discontinuities due to the presence 
of enlarged MUs.
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The CMAP scan
The compound muscle action potential (CMAP) scan is a single channel surface EMG method and 
can be regarded as an extension of standard motor NCS [49]. The CMAP scan uses the underlying 
physiological principle that every MU has a specific threshold for activation. When the CMAP 
amplitude is recorded in response to gradually increasing stimulus intensity (SI), all MUs are 
successively activated. By plotting the CMAP amplitudes versus the SI, the characteristic pattern 
of the CMAP scan becomes visible (Fig. 5). In addition, the width of the CMAP scan (lowest to 
highest MU threshold) gives an indication of excitability properties of all activated axons [50].   
  The CMAP scan provides clinical information regarding MU and axonal excitability variables that 
cannot be obtained during routine NCS [49-53]. The CMAP scan has the potential to be a valuable 
tool to monitor disease progression in patients with ALS and PMA [54]. MU loss and enlarged MUs 
due to reinnervation is typical in patients with MND and can result in the addition of relatively large 
MUAPs to the CMAP [51]. This contribution is often visible as gaps in the CMAP scan (Fig. 6). Hence, the 
presence of multiple gaps is indicative of MU loss and reinnervation. Currently, a manual procedure is 
required to identify these gaps or so-called steps. In Chapter 2 of this thesis, an automated approach 
is described to extract the visual characteristics from the CMAP scan, which has the potential to 
overcome operator-related variability and to reduce time required for the analysis. 
Motor nerve excitability
Motor nerve excitability testing is also a single channel surface EMG technique, however the protocol 
significantly differs from routine motor NCS by the types of transcutaneous electrical stimuli applied. 
Motor nerve excitability studies enable the estimation of resting membrane potential and the 
dynamic changes of the membrane potential after de- and hyperpolarization. The dynamic changes 
in membrane potential are caused by the activation of ion channels, located at the nodes of Ranvier 
and inter-nodal segments. Motor nerve excitability testing has already been applied in various 
neuromuscular disorders. It reveals axonal excitability properties, which cannot be obtained with 
routine NCS [10]. In ALS, several excitability studies have shown abnormalities in axonal excitability, 
which have been associated with the occurrence of fasciculations [55-57]. A plausible explanation for 
the increased excitability was thought to be the combined effect of increased sodium and decreased 
potassium conductance [55-58]. These abnormalities were more pronounced at the distal motor axon 
[57, 59]. Motor nerve excitability testing may help to gain insight into the pathophysiological changes 
in patients with ALS and PMA. In Chapter 5 of this thesis, this technique is combined with HDsEMG 
to investigate the pathophysiological excitability changes of a type of ectopic MU activity, known as 
electrically evoked multiplet discharges (MDs), which will be introduced hereafter.
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Figure 7. Example of a high-density flexible grid (interelectrode distance of 4 mm) with 9x14 electrodes positioned over 
the thenar muscles.
High-density surface EMG 
High-density surface EMG (HDsEMG) makes use of a grid of multiple densely spaced electrodes 
placed over a muscle (Fig. 7). In The Netherlands, developments and applications in this field were 
initiated in the department of Clinical Neurophysiology at the Radboud University Medical Centre in 
Nijmegen [60-68]. In parallel, several other international researchers have been working in this field 
[69-78]. Multichannel surface EMG signals allow the recording of not only temporal information, but 
also spatial information of muscle activity (Fig. 8 and 9). The spatial information gives an anatomical 
position to the MU in a muscle. The MUAP is presented by its spatiotemporal profile, or fingerprint. 
The most important advantage is that by the presence of topographical information, the recording of 
individual MUs (either voluntarily recruited, spontaneous or electrically activated) and their changes 
due to pathology become more reliable and non-invasively accessible. Several clinical applications 
using HDsEMG based on the unique information on individual MU level are discussed hereafter.    
Motor unit number estimation 
MND is characterized by the loss of functioning motor neurons. Therefore the number of motor neurons 
and the rate at which they are lost is likely to be a suitable marker for the severity of the disease and 
its progression. Because a MU consists of a single motor neuron together with all the muscle fibers 
it innervates, the number of MUs equals the number of functioning motor neurons. Several studies 
in patients have shown that serial motor unit number estimation (MUNE) can be used to estimate 
the rate of progression of ALS [79-82]. By using HDsEMG to estimate the number of motor units, 
individual MUAP can more reliably be detected and therefore a larger sample of individual MUAPs can 
be collected compared to conventional single channel surface EMG techniques. Therefore, the motor 
nerve is electrical stimulated along several sites. At every site, the stimulus intensity is increased until 
an all-or-none response of an individual MUAP appear. Stimulus intensity is further increased up to a 
CMAP amplitude where a few individual MUAPs are active. These MUAPs also contribute to the CMAP 
scan at low stimulus intensity level. The number of MUs is then estimated by dividing the maximum 
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CMAP amplitude (all active MUAPs; 100%) by the mean amplitude of the collected MUAPs [60, 63]. 
MUNE using HDsEMG has been applied in Chapters 2, 5 and 7 of this thesis. The benefit of MUNE 
using HDsEMG is that it may serve as a gold standard for the number of functioning MUs and can also 
be applied as an objective measure to relate the total number of MUs to MUs expressing ectopic MU 
activity. 
Motor unit tracking
Current methods for estimating the number of MUs and evaluating their function rely on a comparison 
of samples of MUs. Comparing samples of MUs during the course of the disease, may yield only 
indirect information of pathophysiological changes in individual MUs. To obtain more direct evidence 
of possible pathophysiological changes of individual MUs at various stages of the disease, the same 
MUs need to be tracked longitudinally [83, 84]. However, this is extremely difficult, because properties 
of individual MUs which allow their repeated identification are also properties that may change with 
age or in neurogenic disease. Recently, a more powerful motor unit tracking technique, based on 
HDsEMG recordings, has been developed at our department and it showed that individual MUs 
could be detected and followed in subsequent sessions in healthy subjects [85]. Following individual 
MUs over time may yield information on the life cycle of a single MU and on the pathophysiological 
changes involved in patients with ALS and PMA [86]. To ensure that the observed changes can reliably 
be ascribed to pathology, other effects need to be taken into account as well. Further development 
to improve the reliability of this technique to detect pathophysiological changes will be discussed in 
Chapter 3 of this thesis. 
0.1mV
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Figure 8. Example of a 0.5 sec HDsEMG recording in the thenar muscles of an ALS patient. Fourteen electrode channels 
were selected from the HDsEMG grid. Two MUAPs are visible having different spatiotemporal profiles. 
             A                  B
30 ms
0.25 mV
Figure 9. (A) A MUAP fingerprint recorded with the 9 x14 electrode grid in the thenar muscles of an ALS patient after a 
single stimulus at the threshold intensity of the depicted MU. The MUAP signal is located at the mid-lower left corner of 
the electrode grid. (B) An MD (doublet) in the same MU as in (A) in a consecutive single stimulus. Each signal in the profile 
corresponds to the position in the electrode array of the electrode with which the signal was recorded. Electrodes with 
poor skin contact are visible as flat lines.
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Ectopic motor unit activity as fasciculation potentials 
By using HDsEMG, the spontaneous activity of individual MUs, hence also the recording of FPs [21, 75, 
87, 88], becomes accessible (Fig. 8). The abundant nature of FPs raises the clinical suspicion of MND in 
a symptomatic person. However, no study has yet attempted to quantify the abundance of FPs on an 
individual MU level occurring in a specified time interval to determine their clinical importance. This 
could probably be due to the fact that needle EMG methods are only sensitive to activity of a few MUs 
surrounding the needle tip. HDsEMG enables the recording of a much larger sample of MUs, giving a 
better impression of the functioning of MUs in a muscle. Furthermore, HDsEMG is non-invasive, which 
makes it possible to perform longer and more stable recordings than needle EMG. By registering 
the ectopic MU activity in the form of FPs in a standardized setting within a predefined interval may 
therefore be of clinical relevance. This novel and promising approach will be investigated in Chapter 4 
of this thesis. 
Ectopic motor unit activity as multiplet discharges after electrical stimulation
Recently, multiplet discharges (MDs) occurring after electrical stimulation have been observed and 
have been proposed as an approach to study excitability changes in the distal part of the motor 
neuron [89]. MDs are the re-occurrence of the same MUAPs within 20ms after the first MUAP. In Figure 
9 an example is shown of the same MUAP without (Fig. 9A) and with an MD after a single stimulus (Fig. 
9B). Currently, very little published information is available of these electrically evoked MDs [90, 91]. 
This is probably related to the fact that they have a small probability to occur after a single stimulus 
Additionally, MDs may not be recognized during conventional NCS using single channel surface EMG 
due to superimposition of multiple MUAPs and the relative small number of stimuli applied. Due to the 
availability of additional spatial information during HDsEMG the recognition of individual MUAPs, and, 
hence, the detection of MDs is facilitated. The occurrence of MDs may probably be related to axonal 
excitability changes at the distal motor end [30]. However, for electrically evoked MDs, evidence for 
such an association is lacking. This thesis aims to study MDs together with motor axonal excitability 
testing to improve the understanding of MDs and to assess their clinical significance. Till now, 
electrically evoked MDs have only been systematically studied in patients with ALS and PMA and in 
healthy controls [89]. Studying this phenomenon in patients having MND in their differential diagnosis 
will give more insight into the diagnostic significance of MDs. In Chapters 5, 6 and 7 of this thesis, the 
pathophysiological and clinical significance of electrically evoked MDs as a neurophysiological feature 
in ALS and PMA will be further investigated. 
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IV Aims and outline of thesis
The ectopic MU activity in the form of FPs and electrically evoked MDs seems to give electro-
physiological signs of affected MUs associated with MND. Therefore, they may have diagnostic and 
prognostic relevance. In this thesis, the study of ectopic discharges of individual MUs in patients with 
ALS and PMA plays a central role by making use of previous described surface EMG methods. More 
generally, the objectives of this thesis are the following:
1)  To evaluate and further improve the available research methods for the non-invasive study of 
individual motor units.
2)  To develop neurophysiological markers of clinical relevance in individual patients with ALS and 
PMA, which can be obtained with these surface EMG methods.
3)  To clarify the pathophysiological and clinical significance of FPs and electrically evoked MDs.
Outline
In Chapter 2, a novel automated method is described that quantifies MU variables from the CMAP 
scan, overcoming previous issues of operator-related variability and a time consuming manual analysis. 
How this automated method, when applied to the CMAP scan, is able to give an impression of the 
pathophysiological changes of MU loss and reinnervation is subsequently illustrated. Afterwards, in 
Chapter 3 a concept of an algorithm is proposed to correct for electrode displacement errors to 
improve the reliability of ascribing MUAP changes to true pathophysiological changes in motor unit 
tracking studies using HDsEMG. In Chapter 4, novel MU discharge properties are identified with the 
aim to optimally differentiate patients with MND from healthy controls using HDsEMG recordings of 
MU activity at rest. To provide an understanding of the pathophysiological significance of electrically 
evoked MDs, in Chapter 5 the presence of electrically evoked MDs is compared with excitability 
properties detected with motor nerve excitability testing. In Chapter 6, the presence of electrically 
evoked MDs is examined in patients with suspected MND to clarify the diagnostic accuracy of 
electrically evoked MDs. Therefore, they are compared with the presence of FPs using needle EMG. 
It is examined in Chapter 7 whether electrically evoked MDs are related to disease progression in 
patients with ALS and PMA. Finally, in the last part, the methodological and pathophysiological 
aspects together with the clinical implications and future perspectives are discussed in Chapter 8. A 
summarizing overview of this thesis is given in Chapter 9.   
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Abstract
Objective: 
To evaluate an automated method that extracts motor unit (MU) information from the CMAP scan, a 
high-detail stimulus-response curve recorded with surface EMG. Discontinuities in the CMAP scan are 
hypothesized to result from MU loss and reinnervation.
Methods: 
We introduce a new parameter D50 to quantify CMAP scan discontinuities. D50 was compared with 
a previously developed manual score in 253 CMAP scans and with a simultaneously obtained motor 
unit number estimate (MUNE) in 173 CMAP scans. The effect of MU loss on D50 was determined with 
a simulation model.    
Results: 
We found a high agreement (sensitivity = 86.8%, specificity = 96.6%) between D50 and the manual 
score. D50 and MUNE were significantly correlated below 80 MUs (r = 0.65, n = 68, p < 0.001), but not 
when MUNE was larger than 120 MUs (r = 0.23, n = 59, p = 0.08).  
Conclusions:  
Discontinuities in the CMAP scan as expressed by a decreased D50 are related to significant MU loss. 
The determination of D50 is objective, quantitative, and less time-consuming than both manual 
scoring and many existing MUNE methods.  
Significance: 
D50 is potentially useful to monitor neurogenic disorders and moderate to severe MU loss.
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Introduction 
The compound muscle action potential (CMAP) scan is a surface EMG method which gives an overview 
of all functioning motor units (MUs) in the investigated muscle. The recording set-up used for the 
CMAP scan is identical to that of standard motor nerve conduction studies. The transcutaneous axonal 
stimulation protocol of the nerve differs, however, since the CMAP scan makes use of the underlying 
physiological principle that every MU has a specific threshold for activation. Hence, recording of the 
CMAP amplitude in response to electrical activation of the motor nerve with gradually increasing 
stimulus intensity (SI) yields a stimulus-response curve, which reflects the successive activation of 
MUs (Fig. 1). This CMAP scan provides clinical information regarding MU size, MU number, and axonal 
excitability which cannot be obtained with conventional supra-threshold CMAP stimulation [1-6]. 
  The CMAP scan can be analyzed automatically by means of a stochastic approach [7, 8]. This 
computationally intensive method focuses on the estimation of the number of functional MUs in 
the investigated muscle [9] and is able to monitor the rate of MU loss in amyotrophic lateral sclerosis 
(ALS) patients [10]. Another approach to CMAP scan analysis is the extraction of several CMAP scan 
features [2]. Of these features, excessive steps (both in size and number) are probably the most 
defining characteristics of CMAP scans in patients with marked MU loss (Fig. 1B) [1-4]. Steps are 
differences between consecutive CMAP amplitudes that are disproportionally large compared to the 
corresponding increase in intensity of the applied stimulus. Differences between consecutive CMAP 
amplitudes in the CMAP scans of healthy subjects tend to be small, resulting in a sigmoidal, smooth 
curve (Fig. 1A). In patients with loss of MUs and/or enlarged MUs due to reinnervation, activation of 
such an enlarged MU results in the addition of a relatively large MU action potential (MUAP) to the 
CMAP [1]. This contribution is often visible as an abrupt jump in the CMAP scan. Hence, the presence 
of multiple steps is indicative of MU loss and reinnervation. 
 
Figure 1. The CMAP scan, or stimulus-response curve, of a healthy subject (A) and of an ALS patient (B), both obtained 
from the thenar muscles in response to electrical stimulation of the median nerve. Note the decreased maximum CMAP 
amplitude and the presence of several discontinuities in the CMAP scan of the ALS patient (arrows).
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Table 1. Characteristics of the subjects whose CMAP scans were used in the evaluation of the performance of D50 versus 
the manual step analysis (A) and in the comparison of D50 vs MUNE (B) EDB = extensor digitorum brevis, GBS = Guillain-
Barré syndrome, CTS = carpal tunnel syndrome, DM = diabetes mellitus type 1, ALS = Amyotrophic lateral sclerosis, PMA 
= Progressive muscular atrophy
Condition
No. of  
subjects
Total No. of  
CMAP scans
Muscle
A) Automated D50 vs Manual step analysis
Healthy 16 96 Thenar
Healthy 31 31 EDB
GBS 25 25 Thenar
CTS 16 16 Thenar
DM 31 31 EDB
ALS / PMA 6 54 Thenar
Total 125 253
B) Automated D50 vs MUNE
ALS / PMA 12 92 Thenar
GBS 51 81 Thenar
Total 63 173
Figure 2. Examples of CMAP scans generated by a simulation model [2] (further explained in section Simulation model) 
in which the number of MUs was changed between 5 and 250 MUs. The CMAP scans show a gradual transition from a 
discrete pattern to a smoother sigmoidal curve. The corresponding values for D50 are provided in the labels above each 
plot.
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  Previous work by Maathuis et al. [6] has shown that the quantification of steps can be valuable for 
monitoring disease progression in patients with motor neuron disease. However, in their procedure 
steps were identified manually and off-line. The manual nature of the step analysis made the 
results vulnerable to intra- and inter-operator variability, and the procedure is time-consuming.    
  Automation could solve these drawbacks and improve the monitoring of CMAP scan changes 
in motor neuron disease. Furthermore, it would allow more direct feedback to the clinician and 
potentially facilitate use of the tool in clinical practice.
 In this study we present an automated method for step analysis that is based on the detection 
and size-ordering of all consecutive differences in the CMAP scan. We hypothesize that this method 
provides similar information to that provided by manual step analysis and that it is useful for 
monitoring disease progression. To evaluate this hypothesis, we analyzed CMAP scans recorded in 
patients with a variety of clinical disorders, some with and others without pronounced MU loss. In 
addition, to validate the method’s ability to detect MU loss, we compared its performance with that of 
a simulation model [2] and with motor unit number estimation (MUNE).
Methods
CMAP scan and MUNE dataset
The CMAP scan and MUNE datasets used in this study were collected as part of previously performed 
and ongoing studies carried out at our hospital [3, 5, 6], according to the standardized protocol 
described below. In all of these studies the experimental protocol had been approved by the 
institutional Medical Ethics Committee in Rotterdam and all subjects had given informed consent.    
  To collect a set of CMAP scans that covered the full range of possible patterns, CMAP scans were 
obtained from healthy subjects and from patients with a variety of neuromuscular disorders. This 
resulted in the inclusion of a total of 253 CMAP scans from 125 subjects, which had previously been 
evaluated manually by expert assessors (see below): 127 CMAP scans of 47 healthy subjects (multiple 
muscles), 25 CMAP scans of 25 Guillain-Barré syndrome (GBS) patients, 16 CMAP scans of 16 suspected 
carpal tunnel syndrome (CTS) patients, 31 CMAP scans of 31 diabetes mellitus (DM) patients, and 54 
CMAP scans of 6 ALS and progressive muscular atrophy (PMA) patients (serial recordings: see Table 
1A). From other studies, we used datasets of CMAP scans and MUNEs that were recorded on the same 
day and in the same muscle. This resulted in 173 pairs of both recordings obtained from the thenar 
muscles of 51 GBS patients and 12 ALS and PMA patients (Table 1B).
CMAP scan pattern analysis and D50 
Figure 2 illustrates the effect of a reduction of the numbers of MUs on the CMAP scan pattern and, 
specifically, the visual change from a smooth sigmoidal CMAP scan to a more discrete pattern when 
the number of MUs declines. In general, amplitude differences between consecutive CMAPs may 
result from the recruitment of new MUs, from alternation and/or from noise.  Alternation refers to the 
variability in the CMAP amplitude resulting from the fact that, when the recruitment ranges of MUs 
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overlap, any combination of these MUs can be activated. The larger a consecutive CMAP amplitude 
difference, the more likely it is that it results from the activation of an additional single MU. The smallest 
consecutive differences are mostly the effect of alternation and noise. This implies that, for diagnostic 
and monitoring purposes, we need to focus on the largest consecutive differences. Therefore, we 
decided to determine the number of largest consecutive differences that are needed to build-up 50% 
of the maximum CMAP: D50.
 To determine D50, the CMAP scan data was post-processed in Matlab (R2012a: The MathWorks, 
Natick, MA). First, the N recorded CMAP amplitudes (Fig. 3A) were expressed as percentage of the 
maximum CMAP and ranked by size:
A = [A
1
,
 
A
2
, A
n
,…, A
N
]
  
where A
1
 ≤ A
2
 ≤ A
n
,…, ≤ A
N
  (1)
with N = 500 in the majority of the recordings (Fig. 3B) and n the sample number.  Then, between 
these ranked CMAP amplitudes, the consecutive differences (Fig. 3C) were calculated:
ΔA = [ΔA
1
, ΔA
2,
 ΔA
n
,…, ΔA
N-1
]  where
  
ΔA
n
 = A
n+1
 - A
n
    (2)
Next, these consecutive differences were again ranked, this time from largest to smallest, and their 
cumulative sum was calculated:
M = [M
1
, M
2
, M
n
,.., M
N-1
]   where  M
1
 ≤ M
2
 ≤ M
n
,…, ≤ M
N-1  
(3)
with M the array of the cumulatively summed ranked consecutive differences (Fig. 3D) and n the 
sample number. Hence, M
1
 equals the size of the largest consecutive difference present in the CMAP 
scan (expressed as percentage of the maximum CMAP), M
2
 the sum of the largest and second largest 
difference, and M
N-1
 = 100. Because we were primarily interested in the largest consecutive differences 
(i.e., the elements of M with low sample number n), a threshold was set at 50% of the maximum CMAP 
(this choice is further discussed in section Evaluation). Finally, D50 was determined as the smallest 
value of n at which M exceeded this threshold. In the presence of reinnervation, enlarged MUs will 
contribute more large MU potentials to the CMAP scan, resulting in a few disproportionally large 
consecutive differences. As a consequence, D50 will decline and when M is plotted versus n, the 
curve will be steeper for low n. Figure 3E shows this effect for a healthy subject (D50 = 39) and an ALS 
patient (D50 = 4).
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Registration
CMAP scan
The CMAP scans were recorded using the CMAP scan application on a Viking Select EMG system (V12, 
Nicolet Biomedical, Madison, WI) as described in detail elsewhere [2, 4-6]. Recordings were obtained 
from the thenar muscles of the nondominant hand or the extensor digitorum brevis (EDB) muscle of 
the left foot by electrically stimulating the median nerve or deep peroneal nerve, respectively (Table 1). 
First, the SI required to elicit the lowest-threshold MUAP (S
0
) and the SI required to elicit the maximum 
CMAP (S
100
) were determined. Then, 500 stimuli (2 Hz, 0.1 ms duration) were applied in a downward 
direction from S
100
 to S
0
. Afterwards, the CMAP scan was checked and occasionally additional stimuli 
were applied in segments of the CMAP scan with relatively few data points. 
 The CMAP scan data (SI’s and corresponding CMAP amplitudes) were imported in Excel (Microsoft, 
Redmond, WA) and subsequently processed in Matlab. For each of the CMAP scans, D50 was 
calculated using the algorithm described above. Values for Step% (summed step size as percentage 
of the maximum CMAP) as derived with the existing manual step analysis procedure were collected 
from previous and ongoing studies [3, 5, 6]. 
MUNE
MUNE was performed using high-density surface EMG (HDsEMG) [11-13] with an array of 126 
electrodes attached to the skin over the thenar muscles. The maximum CMAP amplitude was recorded 
and a sample of 20 – 30 single MUAPs was collected by positioning the stimulator over several sites 
along the median nerve. The MUNE was derived by dividing the maximum CMAP amplitude by the 
mean of the collected MUAPs [12, 13]. 
Simulation model 
Use of a computer model to generate simulated CMAP scans has as an advantage that the D50 derived 
from such a scan can be compared against a known input (number and sizes of the contributing 
MUs). The simulation model used for this purpose has been described previously by Blok et al. [2]. 
Figure 2 shows the effect on the CMAP scan pattern when the input of the model changed from 
250 MUs down to 5 MUs. In parallel with the changes in MU number, the MU size distribution was 
changed from a normal distribution for healthy subjects [14] to a distribution with increased MU sizes 
for a small number of MUs, such as in ALS.  
  In clinical practice, it is often difficult to have S0 and S100 match exactly the onset and offset of 
the curve. Usually, the CMAP scan has “tails” at both its low and its high end. The responses in the 
tails carry no information and may be considered lost for the CMAP scan. If excessive, the resulting 
undersampling of the curve may lead to additional discontinuities and hence spuriously low D50. To 
incorporate this factor, simulations were performed for three conditions: lower and upper tails of 1 mA 
(7%), 2mA (14%), and 3 mA (21%), each on top of the “tight” SI range of 14 mA. 
 In all simulations, the number of stimuli was kept constant at 500, because variation in this number 
also affects D50. The input number of MUs was altered from 5 MUs up to 400 MUs and to each of the 
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MUs in such a pool a MUAP size was assigned. Subsequently, for all three SI ranges sets of 50,000 CMAP 
scans were simulated per pool by randomly assigning activation thresholds to the MUs in each pool. 
These activation thresholds were normally distributed over the SI range. Finally, for each simulated 
CMAP scan D50 was calculated.
Evaluation 
Sensitivity and specificity of CMAP scan classification by D50
As 95% of the CMAP scans from the healthy subjects had a Step% ≤ 18%, this latter value was used 
as threshold to classify all 253 recorded CMAP scans as normal or abnormal. Subsequently, the 
performance of D50 against this “gold standard” classification was assessed by means of a receiver 
operating characteristic (ROC) curve. The ROC curve is a powerful and simple tool for comparing the 
performance of two methods in binary classification [15, 16]. The performance for D50 in discriminating 
normal from abnormal CMAP scans was determined by changing its cut-off value from 1 to 70 in discrete 
steps of 1 and calculating the corresponding sensitivity and specificity. From these data, the ROC curve 
was constructed and the area under the ROC curve (AUC) was calculated. Subsequently, the maximum 
of sensitivity multiplied by specificity was taken to mark the optimal cut-off value for D50.   
  Although the median and peroneal nerves may have somewhat different properties and sensitivity 
to disease, the threshold in Step% that distinguished normal from abnormal CMAP scans was almost 
the same for thenar and EDB muscles (18% vs 19%). Therefore, for the purpose of this study, these sets 
of recordings could be merged.
  All statistical analyses were performed using Matlab (R2012a: The MathWorks, Natick, MA). The 
Lilliefors method was used to test normality. A p-value of < 0.05 was considered statistically different. 
Data from Step% and D50 were not normally distributed (p < 0.05); therefore, the results will be 
presented as median and percentiles.
Choice of threshold at 50% of the maximum CMAP
Another set of ROC curves was generated to evaluate the choice of D50’s threshold at 50% of the 
maximum CMAP. This threshold represents a balance between two aspects: 1) focus on only those 
consecutive differences that with the highest probability represent pathologically enlarged MUs, 
which is optimized by applying a low threshold, and 2) including information of as many MUs as 
possible, which can be achieved by using a high threshold. This balance was investigated by changing 
the threshold from 10% of the maximum CMAP up to 90% of the maximum CMAP in discrete steps of 
10% (D10, D20, up to D90). As above, the classification obtained with the manual step analysis (Step% 
≤ 18%) was used as reference and the AUC was determined for D10 up to D90 separately. Optimal 
cut-off values for D10 up to D90 were determined as described above. The 95% confidence intervals 
(CIs) were calculated and the resulting AUCs were compared [15, 17].
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Figure 4. Step% determined by a human observer versus the automatically determined variable D50 for healthy subjects, 
other subjects (GBS, CTS and DM) and ALS / PMA patients. 
Figure 5. (A) Receiver Operating Characteristic curve for evaluation of the performance of D50 with respect to identifying 
normal and abnormal CMAP scans. Values of D50 varied between 1 and 70. Scans were classified as normal or abnormal 
using the manual step analysis detection method with Step% = 18 as threshold (Step% > 18 is abnormal). The location 
of the circle indicates the optimal cut-off value at D50 = 25, which corresponds with specificity = 96.6% and sensitivity 
= 86.8%. The area under the ROC curve is 0.96.  (B) The areas under the ROC curve (AUCs) for varying threshold Dx (the 
number of sorted differences for which their sum exceeds x % of the maximum CMAP). The arrow indicates the overall 
performance shown in Figure 5A (D50, AUC = 0.96). Error bars represent 95% confidence intervals. 
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D50 vs number of MUs
Two approaches were used to assess the relation between D50 and the number of MUs. First, the 
CMAP scan simulation model was used to generate CMAP scans from which D50 was determined; 
this D50 was then compared to the number of MUs used as model input. Second, from the measured 
CMAP scans D50 was calculated and correlated with the HDsEMG MUNE data. Because D50 and 
MUNE were not normally distributed, Spearman’s correlation was used, taking into account that for 
some patients data were obtained from repeated measurements [18].
 As a third strategy, we used the MUNE corresponding to a measured CMAP scan as input for the 
simulation model and subsequently compared the D50 derived from the simulated CMAP scan with 
the D50 derived from the measured CMAP scan. Because the differences between these two values of 
D50 were normally distributed (Lilliefors test, p > 0.05), the Bland and Altman approach [19] could be 
used to correct for the multiple measurements per subject.  
Results
To illustrate the relation between D50 and the visual pattern of the CMAP scans, in Figure 2 each 
subplot is labeled with the corresponding D50. This reveals a clear, inverse relationbetween the extent 
of discontinuities present and the value of D50. 
  Figure 4 shows D50 against Step% for all 253 CMAP scans, subdivided for healthy subjects, 
ALS/PMA patients, and other subjects (GBS, CTS, and DM patients). Median Step% and median D50 
are shown in Table 2. The ROC curve for D50 in Figure 5A shows how accurately D50 is able to classify 
the CMAP scans as normal or abnormal compared to the manual method with threshold at Step% 
= 18%.  The AUC of D50 was 0.96 (95% CI 0.93 – 0.99), indicating that D50 and Step% perform very 
similarly. The optimal cut-off value was at D50 = 25, with corresponding sensitivity = 86.8% and 
specificity = 96.6%. 
 The AUCs for D10 up to D90 as well as the 95% CIs of the AUCs for D10, D30, D50, D70 and D90 
are provided in Figure 5B. Overall, the AUCs indicate high accuracy compared to Step%. The AUC level 
remained constant up to about D50 – D60 and then decreased. There was no significant difference 
between the highest AUC (for D30) and the AUC for D50 (p = 0.34). The optimal cut-off values 
distinguishing normal from abnormal CMAP scans were at D10 = 3, D30 =12, D50 = 25, D70 = 57, 
and D90 = 122.
Table 2. Median values for manual step analysis by Step% and for D50 with 25th – 75th percentile per subject category
Condition 
(Number of scans)
Manual step analysis 
Step%, Median  
 (25th – 75th  percentile)
Automated method 
D50, Median  
(25th – 75th percentile)
Healthy subjects (127)  5.0 (1.9 – 9.6) 39.0 (34.0 – 57.0)
GBS (25)  6.1 (3.1 – 15.2) 35.0 (31.5 – 46.3)
CTS (16)  6.3 (3.9 – 10.1) 37.0  (31.5 – 46.0)
DM (31) 16.3 (7.8 – 39.2) 38.0  (18.3 – 61.9)
ALS / PMA (54) 47.0 (33.9 – 64.0) 11.0  (6.0 – 27.6)
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 Figure 6 visualizes the results from the two validation approaches, with the curve representing 
the result of the simulations (median over all simulations, with error bars at the 5th and 95th percentile). 
The symbols represent the results from the pairs of recordings. For both, the known number of 
MUs (model input for the simulations and HDsEMG MUNE for the recordings) is shown along 
the x-axis and the D50 calculated from the corresponding CMAP scan is plotted on the y-axis. In 
total 34 measured CMAP scans (and MUNEs) were excluded because of abnormal number of 
stimuli (< 300 or > 700), long tails (< 20% left tail and > 20% right tail), or wide sampling interval 
(> 0.05 mA between successive stimuli). 
  Simulations and measurements show a similar trend. There is a linear increase (number of 
MUs ≈ 2 x D50) in D50 up to 80 MUs; beyond that value D50 levels off. In the presence of 150 or more 
MUs, D50 stabilizes around approximately 38 consecutive differences (5th – 95th percentile = 32 – 45 at 
400 MUs) for the simulated CMAP scans. D50 from measured CMAP scans and MUNE are significantly 
correlated for ≤ 80 MUs (r = 0.65, n = 68, p < 0.001), weakly correlated for > 80 MUs (r = 0.47, n = 71, 
p < 0.001), and not correlated (r = 0.23, n = 59, p = 0.08) for > 120 MUs.  
  Finally, the mean difference Δ D50 between the D50 derived from a simulated CMAP scan with 
a model input equal to a recorded MUNE and the D50 obtained from the corresponding recorded 
CMAP scan was 0, with limits of agreement -14 to + 14. This demonstrated that our simulation model 
generates realistic CMAP scans over a wide range of model inputs.  
Figure 6. Validation of D50 by means of a comparison with the number of motor units present. Symbols: D50 of 
measured CMAP scans versus HDsEMG MUNE from ALS / PMA subjects (square) and GBS subjects (triangle) (n = 139). 
Curve: simulation results comparing the median D50 of simulated CMAP scans with the model input. The error bars 
indicate the 5th and 95th percentile of the solid (realistic tail) curve.
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Discussion
In this study, we have presented an automated approach to obtain information about the number and 
size of functioning MUs from the CMAP scan. Our method focuses on the discontinuities in the CMAP 
scan and we have shown that these discontinuities reflect the process of MU loss and reinnervation 
that occurs in many neuromuscular disorders. Furthermore, we have introduced a variable, D50, that 
can capture the most pronounced visual characteristics of abnormal CMAP scans in a single number. 
  Practically, the CMAP scan can be seen as a useful visual tool, supporting and extending 
conventional electrodiagnostic tests. Little training is required to recognize CMAP scans in the 
presence of a strongly reduced number of MUs as abnormal (Fig. 2). The pattern changes are quite 
obvious to the human eye. However, for applications such as follow-up studies and a more objective 
delineation between normal and abnormal, quantification of these changes is essential. D50 appears 
to meet this need. The numbers in the labels of Figure 2 adequately reflect the visually perceived 
smoothness of each curve, with lower D50 representing more discontinuities.
 In addition to capturing the characteristic visual aspects of the CMAP scan, D50 performs very 
similarly as manual step analysis. Because the latter can be used as a follow-up tool to monitor disease 
progression in ALS [6], the same may be assumed to apply to D50. Probably, the use of D50 will even 
improve the reliability of the CMAP scan as a follow-up tool, because it eliminates intra- and inter-
operator variability. Furthermore, the high correlation between D50 and the number of MUs present 
(Fig. 6) demonstrates that the characteristic discontinuities in the CMAP scans of ALS patients are 
directly related to the underlying pathological process. Hence, we conclude that the easily applicable 
CMAP scan, with its familiar recording set-up, non-invasive nature and quick procedure that is well-
tolerated by patients [5] is a promising tool for clinical and scientific use in neurogenic conditions.
  A limitation to such use of the CMAP scan is that it can be related to MU number only in 
conditions of relatively severe MU loss. When there are more than approximately 80 MUs, the linear 
relation between MU number and D50 levels off (Fig. 6). In these conditions, the CMAP scan becomes 
smoother (Fig. 2), primarily because the number of possible combinations of activated MUs in 
response to stimuli of similar intensity (alternation) far exceeds the number of stimuli applied. This 
has an averaging – and hence, smoothing – effect on the curve. Any model that aims to describe the 
CMAP scan pattern encounters this issue [7, 9]. Applying more stimuli would only slightly mitigate the 
effect of such undersampling, at the cost of significant increases in recording duration and patient 
discomfort.
  When there are fewer than 80 MUs present, however, D50 appears to be useful as a rough 
indicator of this number, with number of MUs ≈ 2 x D50 (Fig. 6). This relation is visible both in the 
simulation studies and in the comparison with MUNE measurements. It must be noted, however, that 
the simulated curve represents an average of many simulated CMAP scans. In individual CMAP scans, 
D50 values can deviate due to alternation, lower and upper tail size, and different MU size distributions 
between subjects, which is reflected in the wide limits of agreement. Similarly, the wide range in 
measurement results indicates that the above equation should be applied with caution in individual 
cases. 
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  In our study, the D50 value that optimally distinguished normal from abnormal CMAP scans was 
25, a value that corresponds to approximately 50 MUs according to the above relation. That is, a CMAP 
scan becomes consistently abnormal when there are fewer than about 50 MUs, a condition that is 
usually met when ALS patients undergo their first-time (diagnostic) EMG [20]. This cut-off value of 25 
was calculated using the findings of the manual step analysis as reference standard. To discriminate 
between normal and abnormal CMAP scans in this analysis procedure, a Step% threshold was set at 
18%. If this threshold was shifted, the AUC curve remained similar to that in Figure 5B (not shown). 
This is relevant because the CMAP scans were performed in two different muscles (Table 1). In the 
present small scale study, there was only a minor difference in the upper limit of normal for Step% 
between thenar and EDB muscles (18% vs 19%) in healthy subjects, but we need to take into account 
the possibility that the two muscles have somewhat different cut-off values. However, considering the 
marginal impact on the ROC curve, the use of muscle-specific thresholds is expected to have only a 
negligible effect on the results of this study. 
   The fact that there was no significant difference in D50 derived from modeled and measured 
CMAP scans with the same number of MUs demonstrates that our relatively simple simulation model 
generates realistic CMAP scans. In turn, this implies that – at least for neurogenic conditions – most 
of the clinically relevant variation between CMAP scans can be explained by the limited number of 
parameters incorporated in the model: the number of MUs, their sizes and the activation thresholds. 
This view is supported by our previous experience with the CMAP scan in various patient populations, 
which showed that processes of MU loss and reinnervation are consistently reflected in CMAP scan 
discontinuities, irrespective of differences in the underlying pathology. This is somewhat similar to the 
characteristic changes observed in needle EMG with neurogenic disorders (e.g., enlarged potentials), 
which are not specific for a particular condition. As changes in D50 apparently relate to a loss of MUs 
and reinnervation rather than to a specific pathology, the nature and extent of this pathology seemed 
not directly relevant for the purpose of the present study. For that reason, we have chosen not to 
describe our patient groups in great detail in the current paper (of course, details may be found in the 
publications on the original studies). In addition, this explains why we considered it justified to merge 
the previously obtained data in such entirely different clinical disorders as ALS and CTS in a single 
dataset. 
  Setting a threshold at 50% of the maximum CMAP and counting only the largest differences 
that contribute to reaching this threshold appears to use the information from discontinuities that 
is available in the CMAP scan optimally. A threshold at 50% provides a balance between including 
information of as many MUs as possible (high threshold) and focusing on only those consecutive 
differences that with the highest probability represent pathology (low threshold). In particular, a 
threshold above approximately 60% (> D60) of the maximum CMAP negatively affects the procedure’s 
performance, due to the increased influence of alternation (between MU variability), MU instability 
(within MU variability), and noise (Fig. 5B).
  In general, the effect of alternation is likely to be larger than that of noise or within-MU variability, 
except in conditions of very few remaining MUs (and low D50). For very low numbers of MUs, the 
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presence of noise or unstable MUs may increase D50: they reduce the consecutive differences and 
hence, more of these would be required to constitute 50% of the maximum CMAP. In addition, our 
experience shows that it is important to clearly instruct the patient to take a comfortable position 
and to relax their muscles as much as possible to minimize movement artefacts. These artefacts may 
impact the CMAP scan’s visual appearance; fortunately, their influence on D50 is usually relatively 
small because of the CMAP size sorting step in the algorithm.
  Other important factors related to the recording are the number of applied stimuli and the 
length of the tails of the CMAP scan. Previous work has shown that applying 500 stimuli provides an 
adequate balance between sufficient sampling of the CMAP scan and the recording duration [5]. As 
the number of applied stimuli influences D50, standardization of this parameter during recording (or 
normalization during analysis) is necessary. The effect of the tails might be mitigated by modification 
of the stimulation sequence so that more stimuli are applied in the intermediate range. This would 
require an adaptive protocol, e.g., one that actively searches for relatively large CMAP amplitude 
differences. How such an optimization protocol would affect D50 and other parameters needs to 
be explored, but it has as a potential benefit that the detected large consecutive CMAP amplitude 
differences can more reliably ascribed to enlarged MUs. 
  We conclude that D50 yields similar MU information as manual step analysis but can be derived 
automatically and, hence, objectively. In addition, we have shown that D50 provides an impression of 
the number of MUs in a range relevant to motor neuron disease. Our method is easy to implement in 
an EMG system and the computational effort is small, which makes it possible to present D50 directly 
to the clinician. Therefore, we believe it has significant potential as a monitoring tool in neurogenic 
conditions. 
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Objectives: 
This study discusses a technique to automatically correct for effects of electrode grid displacement 
across serial surface EMG measurements with high-density electrode arrays (HDsEMG). The goal is to 
match motor unit signatures from subsequent measurements and by this, achieve automated motor 
unit tracking.
Methods: 
Test recordings of voluntary muscle contractions using HDsEMG were performed on 3 healthy 
individuals. Electrode grid displacements were mimicked in repeated recordings while measuring 
the exact position of the grid. A concept of accounting for translational and rotational displacements 
by making the projection of the recorded motor unit action potentials is first introduced. Then, this 
concept was tested for the performed measurements attempting the automated correlation of the 
similar motor unit action potentials across different trials. 
Results: 
The ability to perform automated correction (projection) of the isolated motor unit action potentials 
was first shown using large angular displacements. Then, for accidental (small) displacements of the 
recording grid, the ability to automatically track motor units across different measurement trials was 
shown. It was possible to track 10-15% of identified motor units.
Conclusions: 
This proof of concept study demonstrates an automated correction allowing the identification of 
an increased number of same motor unit action potentials across different measurements. By this, 
great potential is demonstrated for assisting motor unit tracking studies, indicating that otherwise 
electrode displacements cannot always be precisely described.  
Abstract
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Introduction
Motor units (MUs) are the smallest functional elements of the peripheral motor nerve system. 
Neuromuscular diseases affect MUs, either directly or indirectly. The follow-up study of MUs during 
a disease process may, therefore, improve our understanding of neuromuscular diseases. Recently, 
MU tracking using high-density surface electromyography (HDsEMG) has been introduced as a 
neurophysiological technique that enables noninvasive follow-up of single MUs [1]. In this technique 
MU action potentials (MUAPs) are recorded with an array of densely spaced electrodes after electrical 
stimulation of the afferent nerve. In these HDsEMG recordings, each MUAP is presented as a spatio-
temporal profile or fingerprint of the corresponding MU. Use of the characteristic information in the 
fingerprints facilitates detection of the MUAPs in consecutive recording sessions and, hence, allows 
for MU tracking.  
  MU tracking may provide insight into the relationship between MUAP properties and how these 
are affected during disease progression. However, before changes in a MUAP fingerprint between 
sessions can be ascribed to an underlying pathophysiological process, other factors that affect it have 
to be taken into account. It is known that MUAP properties depend on geometrical and anatomical 
factors such as muscle fiber length, signal stability (electrode-skin contact), electrode location, and 
electrode orientation [2]. In particular, even small shifts in electrode position can affect the MUAP 
parameters significantly. 
  In clinical practice, the recording grid can be rotated, translated and bended in a different way 
compared to how it was attached in the previous recording session. In the study of Holobar [3], a 
method was proposed to correct for translational errors for the study of the external sphincter muscle. 
In this study we extend this correction procedure and show how the effects of rotation between 
sessions can be automatically compensated for. We illustrate the approach on a low-force voluntary 
contraction measurement of thenar muscles, following well-defined displacements. 
Methods
Recordings
Test recordings of voluntary contractions were performed on three healthy subjects using a HDsEMG 
grid with 126 electrodes. The diameter of the electrodes was 1.5 mm and they were spaced equidistantly 
in 9 rows and 14 columns with inter-electrode distance of 4 mm, as described in detail elsewhere [1]. 
The grid was placed over the thenar muscles. Initially, four configurations were introduced to illustrate 
the concept using recordings from a single subject, indicated in Figure 1. Additionally, recording grid 
in configuration 1 was used as a reference configuration for 5 additional 2-minute recordings in each 
of 3 subjects: with the grid positioned in reference configuration, and positions rotated for -5, +5, 
-10 and +10 degrees around it, mimicking accidental grid displacement. The approximate reference 
position (configuration 1) is identified as the orthogonal to the direction connecting carpometacarpal 
(CMC) and metacarpophalangeal (MCP) joints of the thumb. This guaranteed the total thenar muscle 
coverage.  
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    A B
Figure 1. (A) Four test recording configurations; arrows indicate the direction from the side of printed circuit board (PCB) 
connector towards the horizontal end of the electrode grid; (B) recording grid in configuration 1. White dot indicates a 
central point for grid rotation.
   A  B
Figure 2. (A) Calculating the positions of electrodes of a rotated grid; (B) additional translation for finding the position 
of the best matching. 
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  In the experimental setup, it was important to ensure that the position of the electrode grid was 
precise, especially in cases of small (intentional) displacements. For this precise positioning, a double-
sided adhesive tape containing small and large gaps was used, with the detailed procedure described 
in Lapatki et al. [4]. 
  Recordings were performed on a single day for each subject, with half-hour break intervals. Visual 
feedback in the form of bipolarly filtered signals was used to assist the subject in establishing and 
maintaining a stable, low-force contraction level, estimated at 1-5% maximum voluntary contraction 
(MVC).  
  All signals were first decomposed automatically, separating each into contributions from 
individual MUs using the algorithm described and verified in Gligorijević et al. [5, 6]. First part of this 
algorithm [6], responsible for MUAP fingerprint extraction using optimal clustering was utilized. This 
yielded sets of MUAP fingerprints for each session.
 Fingerprints that were observed at least 100 times without being superimposed to other MU 
fingerprints (uncorrupted) during the two-minute recording were considered reliable, averaged and 
kept for further analysis.
Artificial recording grid displacement  
To assess the effect of rotation of a grid around its center, we first assign coordinates (x,y) to the 
electrode locations in the original grid placement. After rotation over angle θ, new coordinates (x',y'), 
representing the position of these electrodes are then obtained by multiplication with a rotation 
matrix: 
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To assess the value of a fingerprint in every set of rotated coordinates (x',y'), we use the linear interpolation 
based on originally recorded values. This was done for each temporal sample to obtain a projection 
of a fingerprint on a rotated grid. The rotation procedure is depicted in Figure 2A. The interpolation is 
reliable only in the intersection area (gray) that represents the same physical surface covered by the grid 
in both recordings, while the rest of the values cannot be reliably assessed and were put to zero.   
  Apart from rotation, the in-plane translation of the recording grid is practically inevitable and thus 
has to be taken into account [3]. This translation describes a final transformation of grid coordinates:
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Comparing translated observations can be done only in the intersection area (gray in Fig. 2B). Since 
we can compare only part of each fingerprint, it is necessary to choose a “subgrid” – 6x6 subset of 
electrodes around the place of the highest spike which is subsequently used for comparison. The 
subgrid "subfingerprint" is compared with each possible counterpart of the investigated fingerprint 
with which we attempt to match. The best possible position reveals the translation. This example is 
shown in Figure 2B.  
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  The minimal translational step in both x and y directions naturally equals to one inter-electrode 
distance. This brings a limitation due to the fact that a shifted electrode can measure potentials 
anywhere between 2 neighboring electrodes. We exploit the property that the potentials between 
close electrodes can be assessed correctly due to the dense electrode placement of our recording grid. 
Therefore, we upsample the signal 4 times using bicubic interpolation [7] to increase the translation 
resolution.
 Each fingerprint is upsampled and rotated for a chosen angle, followed by the estimation 
of optimal translation for the comparison with its "non-rotated" counterpart. We proceed with 
downsampling the signal to its original dimensions, and then compare rotated and "fixed" fingerprints 
using 2 parameters: Pearson correlation coefficient and normalized root mean square error (NRMSE). 
NRMSE is calculated using the following equation:
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where z^ represents the estimated shape obtained by clustering, and z the template (exact) form. 
Summation is performed over all samples and channels. The peak of the ratio between these values 
(high correlation and small residue when we subtract fingerprints) indicates MUs that match. Each 
MUAP fingerprint obtained by a "displaced" grid is compared with its best match from the "fixed" grid 
measurement.  The complete procedure goes as follows: the rotation angle is varied and the optimal 
translation is calculated until the best overall result is achieved. Fine tuning is then applied around 
the indicated angle to pinpoint a correct value. The output provides the angle of rotation and the 
displacement in x and y directions.  
Results
For the study with 4 configurations (Fig. 1A) in total, 25 reliable MU fingerprints were extracted with the 
decomposition method. Out of these, 3 MUs could be tracked across measurements: 1 MU appeared 
in 3 configurations (1, 2, 4), and the remaining two were matched across configurations 1 and 2. An 
example for the automatic correction of the specified 45 degrees displacement is portrayed in Figure 
3, showing the correlation and the ratio between correlation and NRMSE. The angle was estimated 
at 42 degrees, translation at -2 and 3 mm displacement in x and y directions respectively. Figure 4A 
and 4B indicate the originally recorded fingerprints from positions 2 and 1 respectively. Seemingly 
different MUs (Fig. 4C) match almost perfectly once the rotational and translational corrections have 
been applied (Fig. 4D). Part of the procedure used to identify translational displacement following the 
rotation can be seen in Figure 4E. The subgrid used for comparison is also indicated. 
 The second part of the study involved 3 subjects and aimed at MU tracking with simulated 
accidental displacements of the recording grid for configuration 1 (Fig. 1A). On average, 5 fingerprints 
per subject could be tracked across one or more measurement configurations.
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 The number of MUs that were found and tracked per subject together with their average 
correlation before and after electrode placement corrections are summarized in Table 1. It was found 
that the indicated grid displacements did not always match the ones extracted by our procedure. The 
largest observed difference was the one for measurement involving subject 1. While the indicated 
angle was 5 degrees, the calculated (and in fact, correct) one was -2 degrees with respect to the 
position 1 ("error" of 7 degrees). This may be the result of relative muscle-skin displacement (due to 
e.g. thumb movement) rather than angle measurement error. On average, estimated displacement 
was within ±3 degrees from the indicated value.
A
B
Figure 3. Correlations (dashed gray) and the ratio correlation/NRMSE (black) between the original and fingerprint 
obtained by adjusting the displaced electrode grid (A) roughly identified angle of rotation (42.5) as a peak of the ratio 
correlation/NRMSE and (B) pinpointed precise value of 42.
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Figure 4. Matching the MUs from displaced grid recordings; (A) MUAP fingerprint obtained using grid rotated over 42o 
with respect to signature from (B); (C) overlaid signatures from (A) and (B) without applying correction spatial transforms; 
(D) overlaid signatures from (B, red) and (C, black) after transform; (E) matching corrected projection of (A) using the 
operators described in the text to identify matching indicated in (D); Gray area indicates the subgrid used to pinpoint the 
translation displacement. 
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Angular precision could be tested on subject 2, where the same 2 fingerprints were found in two 
electrode displacement configurations. Searching for the joint peak of agreement revealed the 
angular ambiguity of 1.6 degrees. Table 2 provides ranges for angular and translational displacements. 
One should note that translational difference values (Table 2) could be provided up to the resolution 
of the adjustment step: 1/4 of the inter-electrode distance (IED) in both directions (1mm). Angular 
displacements should be observed with caution due to the previously indicated (but single case) 
angular ambiguity. 
Table 1. Comparison of the fingerprints from measurements with displaced (rotated and translated) electrode grid, 
before and after applying the in-plane projection adjustment
Fingerprints Average correlation
Subject Extracted Trackable
Before After
correction %
1 51 8 86.3 92.4
2 39 6 84.0 93.4
3 30 3 82.2 90.0
Table 2. Ranges for measured displacements and comparison with the indicated values for all subjects
Subject
Average angular 
displacement 
difference* (˚)
Translational difference** (mm)
X direction Y direction
1 (-1.1)-7 1-4 1-3
2 (-2)- (-3) 2-8 1-4
3 0.7-4 1-6 2-6
* provided as a range of values of differences between an indicated and calculated angles
** provided as a range of absolute values measured in different displacements 
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Discussion 
Even when electrode re-placement between sessions is done with great care, repositioning errors 
may remain. Mitigating the effect of such errors may be expected to improve the reliability of 
ascribing changes in the MUAP to true (patho) physiological changes. Extrapolating the results of our 
pilot study with known displacements indicates how this may be achieved when the replacement 
error is not known.  
  Thus far, MU tracking using HDsEMG has been performed without corrections for recording grid 
displacement [1] or accounting for translational displacements only [3].This implied that correlations 
between identical but displaced MUAPs could be relatively low; indeed, the threshold for considering 
MUAPs to be similar was set to a correlation value of 80% [1, 3]. Being able to automatically adjust for 
re-placement errors might allow for a higher threshold, increasing the specificity. It may also simplify 
greatly the otherwise strict and time consuming procedure for placing the HDsEMG recording grid. 
Furthermore, in our study, correlations of > 80% did not necessarily mean fingerprints could be 
considered the same (data not shown) as was observed with visual inspections. 
  Therefore, we opted to add NRMSE to measure (dis)similarity as well. While correlation reflects 
similarity in shape, NRMSE addresses the relative residue when 2 shapes are subtracted from one 
another. This ratio therefore optimizes on matching criteria between MUAPs to minimize the detected 
similarity between objectively different shapes. 
  After adjusting the projection using rotational and translational operators, significant improvement 
in agreement was observable both visually and numerically via the correlation and NRMSE coefficients. 
Moreover, it was found that this method allows fine-tuning in the order of two degrees in angular 
direction in rotation and a quarter of the inter-electrode distance accuracy in translation. The correction 
procedure maximizes correlations between MUs in different sessions. Hard thresholding on these 
correlation parameters did not enable fully automatic matching in a sense that the visual confirmation 
on indicated "similar" MUs was still necessary. Further insight into methods for rotation and translation 
invariant pattern classification might provide more reliable measures for this purpose (e.g. [8]). To 
define the necessary agreement between fingerprints in order to consider them as originating from 
the same MU, the minimal disagreement between different MUAPs has to be described. Also, it is 
important to investigate and describe the changes that could be ascribed to the remaining modeling 
imperfections such as bending of the electrode grid, and changes in skin-electrode contact. These are 
likely to result with muscle-specific correction functions that take into account both the physiology as 
well as the overall geometry of the recording grid. An obvious starting point would be to include proven 
MUAP propagation models [9-11]. These would enable to differentiate between the physiological 
changes of the muscle, increase the method performance and define its exact limitations when 
comparing healthy MUs. This rule would help to maximize the applicability of MU tracking studies.    
  We addressed the group of complex hand thenar muscles. It is probable that MU tracking would 
prove much easier and applicable on other muscles and thus, enable qualitative increase in these 
tracking efforts.  
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  Finally, this proof of concept study was demonstrated on the case of voluntary contractions, 
granting relatively small number of traceable MUs. This can be explained by several reasons: 1) low 
force voluntary contractions do not strictly guarantee activations of same MUs; 2) a number of MUs 
had to be omitted due to larger interference (overlap) with other MUs; and 3) shapes that could 
arguably belong to the same MUs did not sufficiently match, possibly due to model imperfections 
that disregarded bending of the grid for these very complex muscles. However, in real MU tracking 
practice, electrically stimulated recordings would likely take place instead of voluntary contractions. 
These would enable more precise tracking (accessing limited number of MUs at the same time) and 
eliminate the need for decomposition avoiding obstacles related to it. 
  We presented a method to track MUs across measurements more reliably when a recording grid 
is potentially not perfectly repositioned. The initial results show that the method reliably aligns MUs 
across sessions. This will allow MU tracking with higher precision than currently possible.
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Abstract
Introduction: 
Fasciculations, the spontaneous activity of single motor units (MUs) are a characteristic but nonspecific 
feature of motor neuron disease (MND). We aimed to identify MU discharge properties to optimally 
differentiate MND patients from healthy controls. 
Methods: 
High-density surface electromyography recordings were performed in the thenar muscles during 
10 minutes of rest. MU discharges were detected and classified based on the interspike intervals as 
“isolated”,  “continual” or  “other”  for each active MU.
 
Results:
In patients (n = 30) compared to controls (n = 14), more MUs were active (9 vs 3, p < 0.001), generating 
relatively many isolated discharges (35% vs 10%, p = 0.01). Two or more MUs with isolated discharges 
occurred more frequently in patients compared to controls (24% vs < 1% of 10-second windows, 
p < 0.001).
Conclusions: 
More frequent occurrence of different MUs showing isolated discharges (≥ 2 MUs per 10-sec window) 
allows improved identification of patients with MND. 
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Introduction 
Fasciculations are small, random movements of a muscle that can be present in various disorders 
of the peripheral nervous system as well as in healthy subjects [1-3]. However, widespread 
fasciculations are a prominent clinical feature in motor neuron disease (MND) and they are 
considered highly consistent with MND. The clinical relevance of fasciculations is underlined 
by their incorporation in the electrodiagnostic criteria of amyotrophic lateral sclerosis (ALS) 
[4]. As the electrophysiological equivalent of a fasciculation is a fasciculation potential (FP), the 
identification of FPs forms an essential part of the routine clinical EMG examination in MND. This 
procedure is complicated by the fact that FPs, as spontaneous activity of single motor units (MUs), 
can only be distinguished from other, non-pathological MU discharges by their firing pattern.   
  Currently, the identification of FPs relies on implicit knowledge (pattern recognition) of the 
electromyographer, acquired during his or her training as a medical specialist and in the practice 
of seeing many patients under expert supervision. Explicit, quantitative criteria that define an FP are 
lacking. FPs are often described as the spontaneous, irregular discharges of an individual MU [5-7], 
but then “irregular” is rarely specified. Previous studies have shown a wide range of discharge rates 
from only a few FPs per minute [8] up to discharge rates of 10 Hz, occasionally containing multiplet 
discharges [9, 10]. In addition, FP firing properties may closely resemble those of MUs that are voluntarily 
activated at low thresholds [11, 12]. Consequently, in clinical practice differentiation between 
normal and pathological (FP) discharges generally is difficult [13]. Yet, misclassification may impact 
diagnosis as well as the understanding of underlying pathophysiological mechanisms [9, 14].   
  In this study, we set out to determine which firing characteristics best set FPs apart from normal 
MU activity. Our first aim was to quantify the firing characteristics and abundance of all MU activity 
at rest for both patients with MND and healthy controls. This MU activity would include both FPs 
and some low-threshold voluntary activity due to incomplete relaxation. For this purpose, we used 
high-density surface EMG (HDsEMG) recordings because they are more comfortable for subjects and 
allow for longer and more stable recordings than needle EMG. Furthermore, this technique has a 
much larger pick-up area, which enables a more complete inventory of activity in a muscle. Second, 
we addressed the question how the observed firing properties can be used to optimally differentiate 
between MND patients and healthy subjects.
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Figure 1. (A) Example of an isolated discharge of an MU in a healthy subject. The signals correspond to a row selected 
from the 9 x 14 electrode grid. (B) Fingerprint of the same isolated discharge. The position of each signal in the profile 
corresponds to the position in the electrode array of the electrode with which the signal was recorded. Electrodes with 
poor skin contact are represented by flat lines. The gray rectangle illustrates the row of electrodes from which the signals 
in Figure 1A originate. 
Identifying fasciculation potentials in motor neuron disease: a matter of probability 69
4
Materials and Methods
Subjects
In total 30 patients (20 men, 10 women; median age 64 years, range 32 - 78 years; median disease 
duration since symptom onset, 17.1 months), clinically diagnosed with either probable or definite ALS 
(n = 20) or PMA (n = 10), participated in this study. Exclusion criteria were clinical symptoms and/or 
electrodiagnostic evidence of carpal tunnel syndrome. Our age-matched control group consisted of 
14 healthy subjects (4 men, 10 women; mean age 65 years, range 41 - 74 years) without any clinical 
history of neurological disorders. The study protocol was in accordance with the principles of the 
Declaration of Helsinki and approved by the medical ethical committee of the Erasmus MC University 
Medical Center, Rotterdam, The Netherlands. All patients gave written informed consent. 
MU discharge registration with HDsEMG recordings
HDsEMG recordings were made using a 126-electrode high-density array attached to the skin over 
the thenar muscles of the non-dominant hand, in combination with an HDsEMG amplifier system 
(ActiveTwo, Biosemi, Amsterdam, The Netherlands) [15]. The reference electrode was attached to the 
dorsal side of the metacarpophalangeal joint of the second finger, and the ground electrode to the 
dorsum of the hand. The HDsEMG signals were sampled at 4096 Hz per channel, band-pass filtered (2 
Hz - 500 Hz), and stored for further processing. The acquisition software allowed visual feedback of the 
EMG activity during the recordings (Fig. 1A). 
  Subjects were asked to take a comfortable position on a clinical examination bed with a pillow 
under their non-dominant hand and to relax their muscles. In case of excess EMG activity during the 
recording, patients were additionally instructed and/or helped to relax their muscles. Each recording 
lasted for 10 minutes (n = 41), except in three patients with recordings of 5 minutes (n = 2) and 8 
minutes (n = 1). Recording for multiple minutes (instead of the 5-10 seconds that are common in 
clinical practice) increased the probability that infrequently firing MUs were captured.
Decomposition into discharges from single MUs
The recorded HDsEMG signals were post-processed in Matlab (R2014a: The MathWorks, Natick, 
MA). The detection and classification of discharges from single MUs (MU action potentials, MUAPs) 
was performed using a decomposition algorithm previously described in detail [16]. This algorithm 
automatically assesses the number of clusters (present MUs) and assigns MUAPs to these clusters on 
the basis of shape similarity within a cluster and differences between clusters. Per MU that was active, 
the output of the algorithm provides a list of discharge times of this unit and a spatiotemporal profile 
(“fingerprint”) of the MUAP over the electrode array (Fig. 1B). Next, extracted clusters were visually 
inspected and, if necessary, adjusted interactively. Clusters were merged when similarities in their 
fingerprints and a matching discharge pattern indicated they originated from the same MU. Clusters 
were subjected to re-classification if they contained misclassified MUAPs (MUAPs with fingerprints 
that were already assigned to another cluster). To ascertain that only true MUAPs (rather than artefacts) 
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were included, only MUs with more than 15 discharges in the 10-minute recording were accepted. 
Finally, all discharges from intervals that included the simultaneous activity of > 8 MUs were excluded, 
as these may have resulted from suboptimal muscle relaxation. 
Quantification of MUAP firing pattern and discharge rate
According to the definition of FPs by the American Association of Neuromuscular & Electrodiagnostic 
Medicine (AANEM), FPs most commonly occur sporadically as single FPs [17], implying that there 
is a relatively long interval before and after the MU discharge without a discharge of the same 
MU. Therefore, as a first approach, we calculated the interspike interval (ISI) before and after each 
discharge. Physiologically, as a lower boundary, voluntarily recruited MUs have an onset frequency 
of approximately 4 Hz [7] or, as its reciprocal, an ISI of 250 ms. We therefore considered discharges for 
which both the preceding and following ISI were equal to or less than 250 ms part of a spike train and 
indistinguishable from voluntary activity. Henceforth, these discharges will be referred to as continual. 
If both ISIs preceding and following a discharge exceeded 250 ms, this discharge was considered to 
meet the AANEM criteria of a single, sporadic discharge and will be referred to as isolated. Finally, if 
one ISI was larger than 250 ms and the other was smaller, a discharge was classified as other.    
  Single MU activity can now be characterized by a combination of these three discharge types. 
Sporadically firing FPs will likely be mainly dominated by isolated discharges. In contrast, voluntarily 
activated MUs are expected to be dominated by continual discharges. However, irrespective of the 
discharge types within a single MU, the absolute number of discharges per MU may vary extensively 
from only a few per minute to a large amount of discharges with firing rates in the range of voluntarily 
activated MUs. Therefore, the numbers of continual, isolated, and other discharges were expressed as 
percentage of the total number of discharges of an MU. This means that the sum of isolated, continual, 
and other MU discharges equals 100%. The joint ISI plot in Figure 2A illustrates these concepts, where the 
two gray areas correspond to the continual discharges (lower left) and the isolated discharges (upper 
right), and the two unmarked areas correspond to the other discharges (upper left and lower right).   
  As a second approach, we attempted to quantify the amount of MU activity at rest. The clinically 
observed abundant random muscle twitching in MND patients may originate from only a single MU 
with many discharges, but can also be due to discharges originating from multiple MUs. Rather than 
merely counting the total number of discharges per patient, we therefore defined the discharge load 
as the number of discharges of a single MU per minute. In addition, the emphasis is commonly placed 
on the sporadic nature of FPs and their supposedly abundant nature. Therefore, we quantified their 
ectopic behaviour by determining how many different MUs showed only isolated discharges. Since 
this number of MUs strongly depends on the duration of the recording, this analysis was performed 
by splitting the full 10-minute recording into 200, 60, and 20 consecutive recording windows with a 
duration of 3, 10, and 30 seconds respectively. Afterwards, in each recording window the number of 
MUs with only isolated discharges was determined. 
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Figure 2. (A) Joint ISI plot, showing the preceding ISI (ISI
n
) and following ISI (ISI
n+1
) of the discharges from a single MU in 
an ALS patient, where the two gray areas mark the continual (lower left) and isolated (upper right) discharges, the two 
white areas mark the other (upper left and lower right) discharges, and (B) its corresponding ISI histogram. Note that 
isolated and other discharges are also present for ISI
n
 and ISI
n+1 
beyond 1000 ms.
Statistical analysis
All statistical analyses were performed using Matlab (R2014a: The MathWorks, Natick, MA). A p-value 
of < 0.05 was considered statistically significant. The Lilliefors method was used to assess normality. 
Data regarding discharge type were not normally distributed (p < 0.05). Therefore, those results are 
presented as median and percentiles. Differences between groups were tested by the Mann-Whitney 
U-test. 
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Table 1. Summary of motor unit discharge characteristics.
MND patients 
median (25%-75%)
Healthy controls 
median (25%-75%) p-value
Number of subjects 30 14 -
Total number of active MUs 242 44 -
Number of MUs (# per subject) 9 (4 – 10) 3 (1 – 4) < 0.001
Discharge load (# discharges / min) 14 (7 – 53) 25 (7 – 72) 0.07
MU action potential size (µV) 28 (17 – 52) 25 (16 – 35) 0.16
Firing rate (Hz) 2.5 (0.6 – 7.4) 6.0 (2.2 – 10.1) 0.001
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Figure 3. The percentage of isolated discharges versus the percentage of continual discharges per MU for all MUs with 
discharges in patients (circles) and healthy controls (squares). All combinations of continual and isolated discharges can 
occur in both patients and controls, including MUs with predominantly isolated discharges.
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Figure 4. (A) Percentage of 10-sec recording windows versus the number of simultaneously active MUs in such a window 
for patients and healthy controls. Curves indicate median and error bars the interquartile range (25% - 75%). (B) The 
percentage of recording windows with a duration of 3, 10, and 30 seconds (simulated by dividing the full 10-minute 
recording in small segments) in which there are ≥ 2 MUs having only isolated discharges (light grey curve, patients; dark 
grey curve, healthy controls). 
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Results
Table 1 summarizes the characteristics of the observed MUs and their discharges in the 30 patients 
with MND and 14 healthy controls. The mean number of MUs that were active during the ten minutes 
of the recording was higher in patients with MND compared to healthy controls. The firing rate of these 
active MUs was lower in patients than in healthy controls, while the mean discharge load tended to be 
lower in patients than in healthy controls (Table 1). The same number of active MUs was found in ALS 
(n = 20) and PMA (n = 10) patients (9 vs 9 MUs, p = 0.71) and the discharge load was also similar 
(16 vs 14 discharges/minute, p = 0.27). To visualize the different firing patterns, Figure 3 shows the 
percentage of continual discharges versus the percentage of isolated discharges for each detected 
MU. This reveals a clear inverse relation, with firing patterns dominated by isolated discharges in the 
top left corner and those with predominantly continual discharges in the bottom right. Figure 3 also 
reveals that there are many MUs with a mix of both discharge types. More importantly, in controls the 
same inverse relation was observed as in patients, with several healthy MUs showing predominantly 
isolated discharges.
 In MND patients compared to controls, MU discharges were classified more often as isolated 
(35% vs 10%, p = 0.01) or other (33% vs 27%, p = 0.04) and less frequently as continual (18% vs 54%, 
p = 0.003). Again, no significant difference was found between ALS and PMA patients.
  Finally, Figure 4A shows the results for the analysis of the number of simultaneously active MUs 
with only isolated discharges, evaluated using a recording windows with a duration of 10 seconds. 
Two or more simultaneously active MUs with only isolated discharges were observed in 28 out 
of 30 patients with MND and in 24% (IQR: 10% - 40%) of the 10-sec recording windows. By contrast, 
this phenomenon was observed only sporadically in healthy controls (in 7 out of 14 subjects and in 
< 1% (IQR: 0% - 5%) of the recording windows). Figure 4B illustrates how the presence of ≥ 2 simultaneously 
active MUs with only isolated discharges expressed as percentage of the recording windows depend 
on the duration of the recording windows. The percentage of recording windows that showed 
≥ 2 MUs with only isolated discharges was elevated in patients with MND compared to healthy 
controls for all recording window durations (3, 10, and 30 seconds), The probability that ≥ 2 MUs with 
only isolated discharges are detected first increases and then stabilizes for the duration of recording 
windows longer than 10 seconds. When using a 30-sec recording window, ≥ 2 simultaneously active 
MUs with only isolated discharges were present significantly more frequently in our patient group 
than in our healthy control group (MND: 28% of the 30-sec recording windows, IQR: 20% - 40%, vs 
healthy controls: 0%, IQR: 0% - 15%, p < 0.001). 
Discussion
In this study we set out to define criteria for identifying FPs, starting from the assumption that these 
criteria should be based on firing characteristics. Existing definitions suggested that FPs can be 
recognized by their sporadic nature [6, 17] or, alternatively, by specific interspike interval histograms 
[9]. In addition, a lower firing rate has also been suggested [18], which was observed in the current 
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study in patients with MND compared to healthy controls. What we further found is that firing 
patterns of active MUs in MND patients are more frequently dominated by isolated discharges and 
less frequently by continual discharges compared to controls. Furthermore, in patients more MUs 
are simultaneously active (Fig. 4). By combining these findings, our quantitative approach objectifies 
that isolated discharges are much more likely to occur in a patient than in a healthy subject. It implies 
that if a specific firing is to be called a FP (pathological discharge), such a judgement is a probabilistic 
one that requires taking into account the context of other MUs that show (or do not show) isolated 
discharges. Of course, other clinical and/or electrophysiological features (fibrillations, giant potentials) 
may also provide information which increases the a priori likelihood that isolated discharges are FPs, 
but difficulties may arise in the absence of such features [19]. 
  These difficulties were encountered when examining only the discharge patterns of single MUs 
in this study. We found that it is not possible to identify firing patterns that are specific for pathology: 
various combinations of isolated, continual, and other discharges can be observed in relaxed muscles 
of both healthy subjects and MND patients (Fig. 3). More specifically and contrary to our expectations, 
in 7 out of 14 healthy subjects MUs were found with predominantly isolated discharges. Whereas 
in the patient group the discharges of the MUs in the relaxed muscle may have been both normal 
(incomplete relaxation) or pathological (FP) in nature, we consider it highly unlikely that the isolated 
discharges in the controls would have resulted from some unknown, underlying pathology in as many 
as seven healthy subjects. Hence, we have to conclude that fasciculating MUs in MND patients cannot 
be distinguished from normal MUs solely by their discharge characteristics. Furthermore, because the 
MU firing pattern, once correctly detected, is independent of recording technique, this conclusion 
appears equally valid for HDsEMG and needle EMG.
  Subsequently, we tried to develop criteria that with a high probability could be ascribed to 
pathology and that make use of the fact that isolated discharges are much more common in patients. 
Figure 4 suggests that a criterion based on the number of simultaneously active MUs with only isolated 
discharges may meet this aim. Alternatively, the number of isolated discharges themselves (optionally 
expressed as percentage of the total number of discharges) might be used. Assessing whether or 
not there is sporadic activity of ≥ 2 different MUs appears very well feasible both with HDsEMG and 
with needle EMG. Such an approach finds further support in the work of Shiga et al. (2000), who 
demonstrated that two consecutive FPs originating from different MUs are pathognomonic for ALS 
[20]. The objective parameters for discharge types and number of MUs with only isolated discharges 
may be implemented relatively easily into an EMG system having an MU analysis program [21, 22]. 
  Of course, the sensitivity, specificity, and optimally discriminating value for these new parameters 
depend on the muscle investigated, recording technique used, and recording duration. Spontaneous 
MU activity differs between muscles in patients as well as in healthy controls [23, 24], and for needle 
EMG, with its more limited uptake area than HDsEMG, the optimal value for the objective parameters 
are expected to be different. Therefore, further studies in other muscles and with needle EMG are 
required to determine appropriate normal values for the number of different MUs showing only 
isolated discharges to assess its diagnostic accuracy. With respect to recording duration, in general 
terms this duration should be as short as possible to make a clinically useful test, but sufficiently long 
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to allow detection of isolated discharges from multiple MUs. A previous HDsEMG study found that 
approximately 70 - 120 seconds are required to detect 1 - 5 FPs [25]. We evaluated the duration of the 
recording windows (3, 10, and 30 seconds) and noted that for windows longer than 10 seconds the 
percentage of recording windows for ≥ 2 MUs showing only isolated discharges stabilizes. In these 
longer windows, some MUs did not exclusively show isolated discharges but also some continual 
discharges and, therefore, were excluded. Our results thus indicate that a recording duration of 
10 seconds usually suffices to detect ≥ 2 MUs with only isolated discharges in patients with MND. 
However, it should be noted that ≥ 2 MUs with isolated discharges was observed in only 24% of 10-
sec recording windows. Therefore, a longer duration may be required when the occurrence of isolated 
MU discharges is low. Finally, in this study only healthy subjects were used for comparison. Therefore 
for further investigation it is very important to define how specific the criterion for the number of 
different MU with only isolated discharges is for patients with MND in relation to other disorders in 
which spontaneous MU discharges are frequently present.
 To discriminate between isolated and continual discharges, in this study a threshold was set at 
250 ms, based on the physiological lower limit of voluntarily recruited MUs. Shifting this threshold 
to slightly higher or lower values did not result in marked changes in the overall curve in Figure 3B 
(not shown). However, a crucial factor that does need to be taken into account in the interpretation 
of our data is to what extent the subjects were able to relax their muscles. The operator needed to 
ensure that the specific muscle under recording was relaxed as completely as possible. We attained 
this situation by positioning the subject comfortably on the examination bed and putting a pillow 
below the hand. Nevertheless, we cannot preclude that some MUs became spontaneously active 
due to non-pathological factors, such as incomplete muscle relaxation or unintentional contraction 
of the muscle [11]. Specifically, isolated discharges may have been induced by unintended subtle 
ballistic-type movements, which have already been reported to cause double discharges [26]. 
  A final factor that must be taking into account is that some of the discharges in our ALS patients 
may have originated from low-threshold motor neurons recruited by the hyperexcitable corticospinal 
system and/or from abnormalities in the cortical inhibitory system (neuronal fasciculations) [9, 27-
29]. The firing patterns of such neuronal fasciculations are basically indistinguishable from those of 
low-threshold voluntarily activated MUs. Hence, we believe it is generally not possible to determine 
the nature of continual discharges. With respect to isolated discharges, however, we conclude that 
it appears to be feasible to distinguish healthy from diseased muscles, but this requires that the 
identification of FPs be considered a probabilistic rather than a deterministic process by taking into 
account the activity of multiple MUs.
   In conclusion, we present a potential clinically relevant method for objective quantification of 
MU discharges. Our results imply that in addition to solely assessing the presence of FPs and their 
abundance during routine clinical EMG, supplemental relevant information can be obtained by 
assessing the number of different MUs from which they originate. This especially can be helpful in the 
early stage of MND, or in clinically unaffected muscles, where FPs might be the only feature present. 
This information can potentially be used to aid in differentiating MND from other disorders.  
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Chapter 580
Objective: 
To determine whether there is a relation between electrically evoked multiplet discharges (MDs) 
and motor axonal excitability properties. We hypothesized that electrically evoked MDs share their 
underlying pathophysiological mechanism with fasciculations.
Methods:
High-density surface EMG and motor nerve excitability recordings of the thenar muscles were 
performed in 22 patients with motor neuron disease (MND) in their differential diagnosis and who 
were referred for EMG examination.   
Results:
Supernormality (hyperexcitable phase following the refractory period) was significantly increased in 
patients with MDs (n = 10) compared to patients without MDs (n = 12) (25.5% vs 17.0%; p = 0.02). 
Depolarizing threshold electrotonus differed significantly between both groups as well (TEdpeak, 
76.6% vs 66.6%, p < 0.01; TEd90-100ms, 51.7% vs 44.3%, p < 0.01). 
Conclusions:
Our findings imply that the same pathophysiological excitability changes are involved in generating 
MDs and fasciculations. Yet, MDs may be quantified more easily, and may be more specific for 
abnormal distal excitability than fasciculations, because fasciculations may originate along the motor 
axon as well as in the neuron cell body.
Significance:
MDs are potentially useful as objective measure of increased distal axonal excitability at individual 
motor unit level and might complement clinical studies in MND.
Abstract
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Introduction 
Altered motor axonal excitability is commonly suggested to provide a mechanism for the generation 
of fasciculations [1-3]. In patients with motor neuron disease (MND), where fasciculations are an 
important clinical feature, several studies have observed changes in axonal excitability as evidenced 
by an increased supernormality, elevated depolarizing threshold electrotonus, and an increase in 
the strength-duration time constant (SDTC) [2, 4, 5]. These changes are believed to originate from 
increased sodium and reduced potassium channel conductance in the distal segments of the motor 
axon [2-4, 6].
 Altered excitability properties may also explain the occurrence of electrically elicited multiplet 
discharges (MDs), which were observed in MND patients in a previous high-density surface EMG 
(HDsEMG) study [7]. Detailed analysis of these distally evoked MDs showed that their spike intervals 
were restricted to the supernormality period. This suggests that MDs result from altered axonal 
excitability in much the same way as fasciculations of distal axonal origin [8]. 
 If electrically elicited MDs and fasciculations do indeed arise from the same membrane instability, 
this may imply a similar diagnostic significance in MND patients [9, 10]. However, whereas fasciculations 
appear at random and may originate at various anatomical sites including the cell body [8, 11-15], MDs 
have the benefit of being highly localized (in the most distal part of the axon) and under control of the 
investigator. As yet no relation has been established between MDs and the above mentioned motor 
nerve excitability changes associated with the generation of fasciculations. Assessing this relation was 
the purpose of the present study. 
Materials and Methods
Patients 
Twenty-two patients (17 men, 5 women; mean age 62 years, range 32 - 78 years; median disease 
duration from symptom onset to recording 15.0 months) participated in this study. All patients had 
MND in their differential diagnosis and after progression of symptoms, were classified according to 
the revised El Escorial criteria as probable or definite amyotrophic lateral sclerosis (ALS) (n = 15) or 
progressive muscular atrophy (PMA) (n = 6). One patient was initially diagnosed with PMA, but due 
to atypical progression of symptoms, some indication of conduction block, and the absence of a 
clinical response to repeated intravenous immunoglobulin (IVIg), a differential diagnosis of multifocal 
motor neuropathy (MMN) could not be excluded. Therefore, this patient will be further referred to as 
“undetermined”. 
 All patients were recruited through our neuromuscular outpatient clinic at the time they were 
referred for an EMG examination. Both MD registration and motor nerve excitability testing were 
restricted to the thenar muscles (cervical region). Hence, the scoring (presence or absence) of 
fasciculation potentials (FPs) recorded by needle EMG during the EMG examination from muscles 
only in this region was considered as relevant for this study. Patients with clinical symptoms and/
or electrodiagnostic evidence of carpal tunnel syndrome were excluded. The median time interval 
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between HDsEMG and motor nerve excitability recordings in the 22 patients was 4.5 weeks. We used 
control data from 29 normal subjects (21 men, 8 women; mean age 39 years, range 23 - 58 years), 
which was available through the Qtrac software [16]. The experimental protocol was approved by the 
medical ethical committee of the Erasmus MC. All patients gave written informed consent. 
Motor nerve excitability testing 
Nerve excitability was assessed using the QTRAC-S software package (TROND-F, version 20/01/2010, 
Institute of Neurology, London, UK). The cathode of the stimulator (Red dot electrode; 3M Health care) 
was fixed at the level of the wrist over the median nerve; the anode was placed approximately 15 cm 
more proximally on the ulnar side of the forearm. The active recording electrode was attached to the 
skin over the abductor pollicis brevis muscle (APB) and the reference electrode was placed over the 
interphalangeal joint of the thumb. A ground electrode was placed at the base of digits 3 and 4. Skin 
temperature was kept > 30 oC and measured near the stimulation site during the study. 
 The protocol consisted of five tests. In short, in the initial test, a stimulus-response curve was 
derived and used to set a target response (40% of maximum CMAP amplitude) for the other four 
excitability tests (strength-duration, recovery cycle, threshold electrotonus, and current-threshold). 
In the strength-duration test, the change in stimulus intensity required to reach the target response 
was obtained for different stimulus durations. To assess the recovery cycle, after every supramaximal 
conditioning stimulus a test stimulus was applied at varying time intervals to determine the changes 
in axonal excitability. In the threshold electrotonus and current-threshold (I/V) relationship tests, a 
conditioning stimulus was applied to depolarize or hyperpolarize the axons. In general, a depolarizing 
current increases the excitability of an axon, decreasing the strength of the subsequently applied test 
stimulus that is necessary to elicit the target response. A hyperpolarizing current has the opposite 
effect. The strength of the test stimulus required to elicit the target response is automatically adjusted. 
By varying the intensity and duration of the conditioning stimulus and by applying test stimuli at 
varying intervals during or just after the conditioning stimulus, axonal membrane properties can be 
characterized [17, 18]. 
MD registration with HDsEMG recordings 
To detect MDs we used a 126-electrode high-density array attached to the skin over the APB in 
combination with an HDsEMG amplifier system (ActiveTwo, Biosemi, Amsterdam, The Netherlands) 
[19]. The reference electrode was attached to the dorsal side of the metacarpophalangeal joint of 
the second finger, the ground electrode to the dorsum of the hand. The stimulator (circular felt-pad 
electrodes, diameter of 5 mm) was positioned over several sites along the median nerve, all in vicinity 
of the site of the cathode in the motor nerve excitability tests. At each site, stimulus intensity was 
gradually increased until a few (usually 4 to 6) MUs were activated, according to the visual feedback 
of the response on HDsEMG. Since most MUs that generate MDs are known to do so in response 
to only a small percentage of applied triggers, many stimuli may need to be administered to elicit 
and detect an MD. Therefore, subsequently 500 stimuli (2 Hz, 0.1 ms) were applied at each site, and 
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responses were recorded. In this way, up to approximately 20 different motor unit action potential 
(MUAP) profiles were collected per patient. Finally, the maximum CMAP amplitude was recorded and 
divided by the mean of the collected MUAPs to derive a motor unit number estimate (MUNE), as 
described in more detail elsewhere [20].
 MD analysis was performed by post-processing the HDsEMG recordings in Matlab (R2013a: The 
MathWorks, Natick, MA) using previously described decomposition software [20, 21] that was slightly 
adapted to facilitate MD analysis. In contrast to single-channel surface or needle EMG, HDsEMG 
presents a MUAP as a spatiotemporal profile. The extra spatial MU information provided by the array 
of electrodes aids the recognition of single MUAPs during decomposition. The result of this analysis 
is an overview, listing per stimulation site, per MUAP profile found, and for each of the 500 applied 
triggers whether or not the MU corresponding to a MUAP profile was activated by the trigger. Not all 
MUs were activated all 500 times, due to the probabilistic nature of MU activation near the activation 
threshold. 
 Subsequently, the decomposed recordings were checked visually for the presence of MDs 
according to the following three criteria [7]. First, any extra discharge needed to have an identical 
spatiotemporal profile as the MUAP M-wave (direct response). Second, the M-wave with the extra 
discharge needed to be identical to the regular M-wave without extra discharge. Last, the extra 
discharge should occur within a time interval of 20 ms following the M-wave (Fig. 1). For every MU 
that generated at least one MD, the number and type of MDs (doublet, triplet, etc) was established. 
Other variables that were determined included the total number of MUs showing MDs, the absolute 
number of MDs, and the relative number of MDs as percentage of the total number of M-waves. 
A
0.50mV
B
Figure 1. Example of a spatiotemporal MUAP profile recorded with the 9x14 high-density electrode array and evoked 
after a single stimulus in an ALS patient (A). The same MUAP showed a triplet evoked after a single stimulus during the 
same recording (B). The position of each signal in the profile corresponds to the position in the electrode array of the 
electrode with which the signal was recorded.
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 In some of our patients, the disease had progressed further than in others. In more advanced MND, 
fewer MUs will have survived, which might lead to a reduction in the number of MDs per recording. 
Yet, disease progression may also lead to more pronounced excitability changes and, hence, to more 
MDs. To investigate these effects, we determined the number of MDs per surviving MU, by dividing 
the number of MDs by the MUNE, and correlated this number with supernormality.
Statistical analysis
Statistical analyses were performed for the strength duration time constant (SDTC), supernormality 
at 10 ms, and for the depolarizing threshold electrotonus variables TEdpeak and TEd90-100ms. Data 
are shown as mean ± standard error of the mean (SEM). Because excitability is influenced by age 
and temperature, the data of the control subjects were age- and temperature-adjusted according to 
previously established relations [16, 22] before statistical analysis to be able to compare them with 
our measurements. The Shapiro-Wilk test showed that the data was normally distributed. One-way 
ANOVA was used to determine differences between group means and Bonferroni post-hoc testing 
was applied when comparing differences between multiple groups. The relationship between 
supernormality and MDs per surviving MU was analyzed using a Spearman’s rank correlation test. 
Statistical tests were performed using Matlab (R2013a: The MathWorks, Natick, MA) or SPSS (Version 
21.0, Inc., Chicago, IL). A p-value of < 0.05 was considered statistically significant. 
Results
MDs were found in 10 patients (7 ALS, 2 PMA, 1 undetermined). The number of motor units (MUs) 
showing MDs varied from 1 to 5 per patient, with a study total of 21 MUs showing 135 MDs. The MDs 
were observed following 1.9% of the stimuli that triggered M-waves of these 21 MUs. Most of the 
MDs were doublets (133 of 135). In one ALS patient triplets were found (2 of 135). The occurrence 
of MDs in the thenar muscles was not related to the disease duration (symptom onset to recording) 
of the patients. To what degree the thenar muscles were involved by the disease was expressed by 
the number of functional MUs estimated by HDsEMG MUNE, which varied from 26 up to 311 with a 
median of 159. MD registration was restricted to the thenar muscles (cervical region). In this region, 
FPs were present in 18 patients (13 ALS, 4 PMA, 1 undetermined). One ALS patient showed MDs in the 
absence of FPs.
 Figure 2 illustrates the results of the recovery cycle, threshold electrotonus, and current-threshold 
relationship tests for patients with electrically evoked MDs, patients without electrically evoked MDs, 
and healthy controls. Further statistical analysis showed no significant difference in SDTC between 
patients that showed MDs and patients without MDs (0.46 ± 0.02 ms vs 0.48 ± 0.03 ms, p = 1.00). In 
the recovery cycle, the supernormality at 10 ms was significantly increased in patients with MDs (25.5 
± 2.9% vs 17.0 ± 2.1%; p = 0.02, Fig 2A) when compared to patients without MDs. The depolarizing 
threshold electrotonus (TEd) variables also differed significantly between these two subgroups 
(TEdpeak, 76.6 ± 2.6% vs 66.6 ± 1.7%, p = 0.001; TEd90-100ms, 51.7 ± 2.0% vs 44.3 ± 1.5%, p = 0.003; 
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Fig 2B). The undetermined patient showed large supernormality at 10 ms (39.9%) and fanning out in 
the threshold electrotonus test (TEd90-100ms = 59.0% and TEh100 = -173.0%). Furthermore, axonal 
degeneration was also present in this patient as the number of MUs was markedly reduced (MUNE = 27).
 As ALS and PMA are often regarded to be part of the same clinical spectrum [23, 24] and since 
we did not find any excitability differences between these subgroups, we merged them for the 
comparisons with the healthy controls.  When the 21 ALS and PMA patients were thus compared to 
the healthy controls (n = 29), a significant difference was found for the SDTC (0.47 ± 0.02 ms vs 0.40 
± 0.02 ms; p = 0.01), the supernormality at 10 ms (20.0 ± 1.8% vs 13.0 ± 1.1%, p = 0.001), and for the 
depolarizing threshold electrotonus (TEd) variable TEdpeak (70.2 ± 1.7% vs 66.1 ± 0.9%, p = 0.02). 
TEd90-100ms (47.1 ± 1.4% vs 44.3 ± 0.8%, p = 0.06) was not significantly different. Finally, when the 
number of MDs was normalized for the number of functional MUs present (to compensate for axonal 
degeneration), a significant correlation was found between supernormality at 10 ms and the number 
of MDs (as percentage of the number of stimuli applied) per MU (r = 0.47; p = 0.03). 
Discussion
In this study, we used two electrophysiological methods, one measuring excitability properties directly 
and the other addressing ectopic axonal activity, to clarify the pathophysiological mechanisms in 
patients showing electrically evoked MDs. Our results demonstrate that axonal excitability is increased 
in patients in whom MDs can be found but not in patients without MDs.
 The differences in excitability properties between healthy controls and the  21 MND patients that 
we observed are consistent with previous findings [2, 4-6]. The prolonged SDTC reflects increased 
persistent Na+ channel conductance. An increased supernormality can result from either membrane 
hyperpolarization or a reduction in K+ conduction [2, 4]. Of these two possibilities, the latter seems 
to be the most likely explanation, as membrane hyperpolarization could only partly account for the 
observed excitability changes. Furthermore, it has been shown in previous studies that a reduced 
K+ conductance is associated with the occurrence of fasciculations [2, 4-6]. Due to the reduced K+ 
conductance, an imbalance may arise between the inward sodium and outward potassium currents. 
This imbalance can result in axonal hyperexcitability, increasing the probability that an axon generates 
a spontaneous discharge (fasciculation). 
 Our present findings demonstrate that the altered excitability properties which have been 
suggested to result in fasciculations are also related to the presence of electrically evoked MDs. MDs in 
MND have a distal origin and they probably originate at the terminal branches, which is also thought 
to be the trigger site of distal fasciculations [3, 7, 8]. In line with this view, after blocking of presynaptic 
K+ channels, a single electrical trigger has been shown to be able to induce repetitive discharges 
[25, 26]. Hence, this implies that a single mechanism (a reduced K+ conductance associated with 
axonal hyperexcitability that increases the probability of spontaneous activity) may explain both 
fasciculations and MDs. 
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 In this context, it is interesting to look in some more detail at the single included patient showing 
electrically elicited MDs with the as yet undetermined diagnosis as our aim was to establish the 
relation between altered motor axonal excitability and electrically elicited MDs. This patient who 
met the inclusion criteria had a high supernormality, fanning out, and a small number of functional 
axons. Previously, such excitability changes in MMN patients have been ascribed to membrane 
hyperpolarization just distal from the conduction block [27]. It was suggested that at the level of 
the lesion, the membrane becomes depolarized due to an increase in extracellular K+ concentration. 
At the same time, surrounding segments become hyperpolarized, as the result of increased, 
compensatory electrogenic pump activity. This effect of local membrane de- and hyperpolarization 
was associated with fasciculations [28, 29]. Since our undetermined patient also showed MDs, again 
we may tentatively assume a common mechanism here. This implies that these excitability changes 
could also be evaluated on a single motor axonal level by the detection of electrically evoked MDs in 
a controlled and objective manner.
 Fasciculations are well established in the diagnosis of MND in current practice recommendations 
[9, 30]. They are thought to arise both from central regions, at the motor neuron cell body, and at the 
motor axon [8, 11-15]. Spontaneous (not electrically activated) MDs, just as fasciculations, are known 
to occur in MND patients but are also relatively common in healthy subjects [31-34]. With respect to 
MDs in healthy subjects, several studies have suggested a proximal (motor neuronal cell body) rather 
than axonal origin [31, 35, 36]. Furthermore, we have previously studied electrically evoked MDs and 
did not observe any in 10 healthy subjects and a total of 300 MUs [7]. 
 Based on this collective evidence, we tentatively assume that spontaneous activity (whether 
fasciculations or MDs) originating proximally can be normal, whereas distally generated ectopic 
discharges are usually abnormal. If so, an important clinical implication would be that diagnostic 
approaches that can selectively address ectopic discharges that originate in the distal axon might 
have a higher specificity for abnormal motor axonal function. In general, registration of fasciculations 
does not allow discrimination as to their origin unless highly specialized techniques to determine 
the firing pattern are used [8]. By contrast, with electrically elicited MDs we are able to study distal 
excitability changes in isolation. 
 Registration of MDs as applied in the current study has as another advantage that MDs may be 
quantified more easily: the number of applied stimuli is known and under the control of the operator. 
This makes our approach a potentially valuable, objective addition to current electrodiagnostic tests. 
Furthermore, MD registration focuses on single, possibly affected MUs, whereas excitability tests study 
groups of axons amounting to 40% of the functional axons present. In earlier phases of the disease, 
abnormalities in excitability testing can be obscured due to a relative low number of affected MUs 
included in the 40% CMAP target response. Therefore, MDs are potentially more sensitive to observe 
pathophysiological changes in the early phase of MND, when only a few MUs are affected. Still, the 
probability that an electrical stimulus elicits an MD remains small. This is probably why not all ALS 
and PMA patients showed MDs. Considering the previously established relation between excitability 
properties on the one hand and disease progression and prognosis in ALS on the other [5, 37], further 
investigation seems warranted. 
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 A limitation of the present study is that the excitability recordings were made at the level of 
the wrist whereas MDs in MND originate more distally, at the level of the nerve terminal branches 
[7]. Hence, the two tests address different sections of the axon and as the biophysical properties 
at the nerve terminal branches differs, this difference influences the excitability measures [3, 38]. 
Excitability studies focused on a more distal part of the motor axon could provide further insight 
into the genesis and relation between electrically evoked MDs and FPs. However, as excitability tends 
to be most abnormal at the most distal site, our study design probably results in under- rather than 
overestimation of the relation between MDs and axonal excitability. 
 Second, we recognize that our use of the Qtrac data as normal control set may appear to be a 
limitation of the study. However, we did collect a control data set prior to and with test conditions as 
in our current study, which showed no significant deviation from the Qtrac data. We chose to use the 
Qtrac data as control set because it is widely available in the research community and hence, its use 
in a possible replication study would eliminate one source of potential differences. We also believe 
that setting our patient data against a “gold standard” facilitates future comparisons of these data with 
other findings. 
 Another factor that may have influenced our results is the prescription of Riluzole (100 mg/
day) to all ALS and PMA patients at the time of the excitability tests. Recent findings suggest that 
administration of Riluzole results in a decreased supernormality and a non-significant reduction in 
depolarizing threshold electrotonus [39]. If Riluzole normalizes excitability, this factor probably does 
not affect our main conclusion, because our findings would likely have been more explicit when we 
had examined the patients prior to using this drug.
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Objective: 
To determine and compare the diagnostic accuracy of electrically elicited multiplet discharges (MDs) 
and fasciculation potentials (FPs) in motor neuron disease (MND).
Methods: 
Patients were eligible when they had MND in their differential diagnosis and were referred for 
electromyogram (EMG). Stimulated high-density surface EMG of the thenar muscles was performed 
on the same day as standard EMG examination. High-density recordings were analysed for presence 
of MDs and needle EMG of any muscle investigated in the cervical region for presence of FPs.
Results: 
Of the 61 patients enrolled in this diagnostic study, 24 patients were clinically diagnosed with 
amyotrophic lateral sclerosis (ALS) and 11 patients with progressive muscular atrophy (PMA). Another 
diagnosis was made in 26 patients. Sixteen patients in whom MDs were detected were diagnosed 
with either ALS (n = 11) or PMA (n = 5) (sensitivity = 47.1%, PPV = 94.1%). MDs were detected in only 
one patient initially diagnosed with PMA, but in whom later on multifocal motor neuropathy could 
not be excluded (specificity = 96.2%).   Electrically elicited MDs had a higher specificity than FPs (96.2% 
vs 53.9%, p < 0.001, n = 26) and lower sensitivity (47.1% vs 85.3%, p = 0.002, n = 34). When considering 
presence of MDs in MND as neurogenic EMG abnormality, lower motor neuron involvement of ≥ 1 
EMG region increased from 50.0% to 73.5% (p = 0.008, n = 34).
Conclusions:
Electrically evoked MDs are highly specific for ALS and PMA and are an early sign of lower motor 
neuron dysfunction.
Abstract
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Introduction
Establishing the diagnosis of amyotrophic lateral sclerosis (ALS) or progressive muscular atrophy 
(PMA) tends to be a challenging task due to a clinically heterogeneous presentation and the absence 
of a reliable biomarker. Owing to the disastrous course of these forms of motor neuron disease (MND), 
accurate and early diagnosis is of importance. Yet, currently the diagnostic delay is about 12 months 
[1]. According to the latest electrodiagnostic criteria [2], neurophysiological evidence of lower motor 
neuron (LMN) dysfunction should be considered equivalent to clinical evidence, which underlines the 
importance of the electrodiagnostic examination. Any electrophysiological measure that enhances 
the detection of LMN dysfunction early in the diagnostic phase can, therefore, potentially improve 
the diagnostic process in MND. 
 Electrically elicited multiplet discharges (MDs) may be such a promising measure. The registration 
of MDs has been introduced recently as an approach to study excitability changes in the distal part of 
the axon [3].  MDs are thought to result from the same pathophysiological mechanism as fasciculations 
of distal origin and may, therefore, have similar diagnostic significance [4].  Fasciculations may also arise 
at the soma, however, and spontaneous activity of the soma, whether in the form of fasciculations or 
MDs, is relatively common even in normal conditions [5,6].  By contrast, distal spontaneous activity in 
healthy subjects appears to be rare [3].  Hence, we hypothesized that the specificity of distally evoked 
MDs for ALS and PMA might be higher than that of fasciculations and set out to assess the diagnostic 
accuracy of electrically elicited MDs and fasciculations following the STARD guidelines [7]. 
Materials and methods
Patients 
Patients were eligible for this study when they had MND in their differential diagnosis and were referred 
by the neuromuscular outpatient clinic of the Erasmus MC Rotterdam to its clinical neurophysiology 
department for an EMG examination. MND did not have to be the most likely diagnosis, as any 
suspicion on clinical grounds sufficed for inclusion. The study was approved by the medical ethical 
committee and all participating patients gave written informed consent. Patients were recruited as 
part of a larger high-density surface EMG (HDsEMG) study [4], where exclusion criteria were clinical 
symptoms and/or electrodiagnostic evidence of carpal tunnel syndrome.
MD registration with HDsEMG recordings 
HDsEMG recordings were performed to obtain electrically evoked MDs as previously described [3].
HDsEMG obtains temporal and spatial information from an array of 9x14 electrodes spaced densely 
over the muscle [8-10]. As a result, it allows collection of a larger sample of different motor unit action 
potentials (MUAPs) than single-channel EMG techniques, and aids the recognition of single MUAPs 
and corresponding MDs if present. 
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 The HDsEMG recordings were made with the array attached to the skin over the thenar muscles of 
the non-dominant hand. The reference electrode was attached to the metacarpophalangeal joint of 
the second finger on the dorsal side and the ground electrode to the dorsum of the hand. A sample of 
up to approximately 20 different single MUAPs was collected by positioning a stimulator over several 
sites along the median nerve. At each site, the stimulus intensity was gradually increased until a few 
(usually 4 to 6) motor units (MUs) were activated, according to the visual feedback of the responses 
on HDsEMG. Since, most MUs that generate MDs are known to do so in response to only a small 
percentage of applied triggers, many stimuli may need to be administered to elicit and detect an 
MD. Therefore, subsequently 500 stimuli (2 Hz, 0.1 ms) were applied at each site, and responses were 
recorded. 
 An MD analysis was performed by post-processing the HDsEMG recordings in Matlab (R2012a: The 
MathWorks, Natick, Massachusetts, USA) using previously described decomposition software [9,10], 
that was slightly adapted to facilitate MD analysis. The result of this analysis showed per MUAP profile 
found, whether or not this MUAP was activated by each of the 500 applied triggers (due to the 
probabilistic nature of MU activation near the activation threshold, not all MUs were activated all 
500 times). In addition, for every MUAP that generated at least one MD, the number and type of MDs 
(doublet, triplet, etc) were established by criteria described elsewhere [3] and registered.
Study design
To detect electrically elicited MDs, high-density surface EMG recordings were performed on the 
same day as the standard EMG examination, which included detection and scoring of fasciculation 
potentials (FPs). An expert assessor conducted the HDsEMG recordings blinded to the results of 
the EMG examination. A resident neurologist performed and evaluated nerve conduction studies 
and needle EMG under direct supervision of an experienced clinical neurophysiologist. The EMG 
examination protocol was based on the differential diagnosis and adapted to EMG findings during 
the examination, and hence, differed between patients. For the same reason, the number of 
investigated muscles also varied between patients. Since MD registration was restricted to the thenar 
muscles (cervical region), only the presence or absence of FPs from muscles in the cervical region 
was considered relevant for the current comparison with electrically evoked MDs. The shape and 
complexity of FPs were not evaluated for the present study. 
 The clinical diagnosis of ALS or PMA was made by an consultant neurologist specialized in 
neuromuscular disorders, based on the symptoms and progression of the disease, neurological 
examination and the results from routine tests, including EMG, MRI, and blood tests that were 
predominantly performed to exclude other disorders that could explain the clinical symptoms. 
The revised El Escorial criteria were applied to categorize the patients with MND as to diagnostic 
probability [11]. The consultant neurologist was blinded to the HDsEMG results. Information regarding 
the neurological examination and patient characteristics was obtained from each patient’s history. 
The vital capacity (VC) and ALS functional score (ALSFRS-R) were measured on the same day as the 
EMG examination. The ALSFRS-R (ALS functional rating scale – revised) is a questionnaire yielding 
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a maximal score of 48 (representing normal functioning) that assesses various aspects of activities 
of daily living over four subcategories (subscores): bulbar, fine motor, gross motor, and respiratory 
[12]. Finally, the clinical diagnosis was reviewed and, if necessary, revised after several months of 
progression of symptoms. Using this clinical diagnosis as reference standard, we determined and 
subsequently compared the diagnostic accuracy of electrically evoked MDs and fasciculations.
Statistical analysis
Statistical analysis was conducted using Matlab (R2012a: The MathWorks, Natick, MA). Differences 
between groups were tested by the Mann-Whitney U-test or Student t-test. The Kolmogorov-Smirnov 
method was used to assess normality. Data is presented as either mean and standard deviation (SD) 
or median with interquartile range (IQR). The diagnostic accuracy of MDs and fasciculations was 
investigated using 2x2 contingency tables. To compare the proportions of patients in whom the 
number of affected EMG regions increased when MDs were used as additional electrophysiological 
parameter, the McNemar exact test was applied. A p-value of < 0.05 was considered statistically 
significant. 
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Figure 1. Schematic flow diagram of patient inclusion and diagnoses according to the STARD criteria. 
*Initial diagnosis of PMA; due to atypical progression, MMN could not be excluded
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Table 1. Patient characteristics
All participating 
patients*  
(n = 61)
Patients with
ALS / PMA*  
(n = 35)
Patients with  
other diagnosis*  
(n = 26)
Age, yrs 58 (47 – 69) 62 (50 – 71) 52 (45 – 61)
Gender, men / women 40 / 21 23 / 12 17 / 9
ALSFRS-R** 43.0 (40.0 – 46.0) 42.0 (37.5 – 43.8) 45.0 (42.0 – 47.5)
VC***, % of predicted 89.4 (74.8 – 95.8) 83.8 (69.0 – 94.3) 92.3 (80.3 – 108.6)
Disease duration****, mnths 18.3 (9.5 – 33.3) 12.2 (9.6 – 22.6) 34.4 (9.5 – 63.6)
* Values in median (25th - 75th percentile), or otherwise when indicated  
** In 8 patients with ALS / PMA and in 3 other patients the ALSFRS-R score was not obtained
*** In 1 patient with PMA and 1 patient with another diagnosis VC measurement was not possible  
**** Symptom onset to the time of EMG examination 
Results
Inclusion started in August 2010 and ended in June 2013. During this period, 61 patients enrolled in 
this study (Fig. 1). Their demographic and clinical characteristics are shown in Table 1. 
 A subset of these patients was also part of a previous study carried out at our hospital [4]. Of the 
61 patients, 24 patients were eventually clinically diagnosed with ALS, 11 patients with PMA, and 26 
patients got another diagnosis (Fig. 1). Based on the revised El Escorial criteria [11], the 24 patients with 
ALS could be categorized after progression of symptoms as having ‘possible’ ALS (n = 1), ‘probable’ (n 
= 1), or ‘definite’ (n = 22) ALS. During follow-up, four patients with PMA progressed to ‘probable’ (n = 
1) and ‘definite’ (n = 3) ALS. One patient, initially diagnosed with PMA, showed atypical progression 
of symptoms. In addition, in a repeated EMG examination, a conduction block was observed, and 
although there was no clinical response to repeated intravenous immunoglobulin (IVIg), a differential 
diagnosis of multifocal motor neuropathy (MMN) could not be excluded. This patient will further 
be referred to as ‘inconclusive’. For the diagnostic accuracy assessment, this patient will be analysed 
as having another diagnosis. No familial cases in the patients with ALS and PMA were present. Ten 
patients with ALS had a bulbar onset of symptoms. By April 2014, 13 (37.1%) of the 35 patients with 
ALS and PMA had died. 
 All 61 patients tolerated the HDsEMG recordings well. VC measurements were not obtained in 
two patients, due to equipment error (n = 1) and inability of the patient to conduct the measurement 
(n = 1). For logistic reasons the ALSFRS-R questionnaire was not scored in the first 11 patients. In 
one patient, clinically diagnosed with PMA, no reliable single MUAP profiles could be obtained due 
to inability to sufficiently relax the thenar muscles. On account of this, statistics were based on 60 
patients or 34 patients with ALS and PMA when involving MDs.
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Figure 2. (A) Example of an M-wave from a MU after a single trigger, recorded with the 9 x 14 electrode grid in an ALS 
patient. (B) An electrically evoked doublet of the same MU as in (a) in the consecutive trigger. The position of each signal 
in the profile corresponds to the position in the electrode array of the electrode with which the signal was recorded. 
Electrodes with poor skin contact are visible as flat lines.
Table 2. Contingency tables for (A) presence/absence of electrically elicited MDs in the thenar muscles of 60 patients, (B) 
presence/absence of FPs in the cervical region in 61 patients.
(A) Outcome of MD analysis using HDsEMG recordings ALS / PMA No ALS / PMA
MDs present 16 1
MDs absent 18 25
(B) Outcome of FP evaluation using needle EMG
FPs present 30 12
FPs absent 5 14
Table 3. Number of body regions involved in the electrodiagnostic evaluation without electrically elicited MDs and with 
MDs (considered as neurogenic EMG abnormality) in the 34 patients diagnosed with ALS / PMA
Number of positive 
EMG regions
LMN dysfunction without 
electrically elicited MDs 
 - , (%)
LMN dysfunction with 
electrically elicited MDs  
-, (%)
p-value
≥ 1 17 (50.0) 25 (73.5) p = 0.008
≥ 2 9 (26.5) 11 (32.3) NS
≥ 3 2 (5.9) 3 (8.8) NS
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 Electrically elicited MDs (Fig. 2B) were found in 11 patients with ALS and in 5 patients with PMA 
and in the ‘inconclusive’ patient. In those 17 patients with MDs, in total 31 MUs were found that 
generated MDs, with 1 – 5 MUs showing MDs per individual patient. From these 31 MUs, in total 333 
MDs were recorded in response to 3.3% of all stimulations. Since not every trigger elicits an MD from 
a MU (Fig. 2A and B), the number of MDs per MU was also expressed as a percentage of the number 
of elicited M-waves. This percentage, a measure of MD persistence, varies between the MUs with 
MDs (Fig. 3). The highest persistence was found in an ALS patient in whom 93 (71%) out of the 131 
triggers that elicited an M-wave showed an MD. Most of the MDs were doublets (331 of 333). In one 
ALS patient triplets were found (2 of 333). There was no significant difference in the number of MUs 
that showed MDs between patients with ALS and PMA (21 vs 9, respectively) nor in MD persistence. 
In the ‘inconclusive’ patient a single MU showed MDs with a persistence of 0.3%. Finally, we found no 
relation between age and the number of MUs showing MDs in patients (r = 0.10, p = 0.43, n = 60). 
 The diagnostic accuracy of electrically elicited MDs was determined by means of Table 2A, which 
shows that the presence of MDs is significantly related to the clinical diagnostic outcome (Fisher exact 
test, p < 0.001, n = 60). Sixteen patients in whom MDs were detected were later diagnosed with either 
ALS (n = 11) or PMA (n = 5) (PPV = 94.1%; sensitivity = 47.1%, CI: 32% - 62%).  MDs were detected only 
in the ‘inconclusive’ patient (specificity = 96.2%, CI: 91% - 100%). 
 The accuracy assessment of fasciculations shows that the presence of FPs in the cervical region 
is also significantly related to the clinical diagnostic outcome (Fisher exact test, p = 0.002, n = 61, 
Table 2B). In 30 of the 35 patients with ALS and PMA, FPs were observed (sensitivity = 85.7 %, CI: 
76% - 95%) as well as in 12 patients with another diagnosis (PPV = 71.4%; specificity = 53.9%, CI: 
39% - 69%): inclusion body myositis, post-polio syndrome, ‘inconclusive’, monomelic spinal muscular 
atrophy, primary lateral sclerosis, neuropathy, plexopathy, hereditary spastic paraplegia, radiculopathy 
(2x), benign fasciculation syndrome, and cervical myelopathy. Overall, compared to MDs, FPs were 
more commonly observed both in patients with ALS and PMA and in patients with another diagnosis. 
This resulted in a significantly higher sensitivity for FPs (85.3% vs 47.1%, p = 0.002, n = 34). By contrast, 
the specificity was significantly higher for electrically evoked MDs (53.9% vs 96.2%, p < 0.001, n = 26). 
 Another perspective on these findings can be obtained by considering the electrodiagnostic 
criteria used to establish the diagnosis of ALS or PMA from the standard EMG examination [11]. 
Of the 34 patients clinically diagnosed with ALS or PMA, 17 patients had ≥1 EMG region with 
electrophysiological signs of LMN dysfunction, 9 patients had ≥2 EMG regions involved, and 2 
patients had ≥3 EMG regions with LMN dysfunction. Would the presence of MDs have been added as 
electrodiagnostic criterium (and considered as neurogenic EMG abnormality), then the percentage of 
patients with LMN involvement of ≥ 1 EMG region would have increased significantly (from 50.0% to 
73.5%, p = 0.008, n = 34; Table 3). 
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Figure 3. Histogram of MD persistence (percentage of applied triggers of a MU that showed an MD) for all 31 MUs. 
Discussion
In this study, we have shown that electrically elicited multiplet discharges appear to be a highly specific 
electrophysiological marker of LMN dysfunction. This finding has important diagnostic implications. 
Of the patients with MND in their differential diagnosis who showed MDs, 94% eventually had ALS or 
PMA. In addition, despite being a well-known clinical hallmark in patients with MND, fasciculations are 
less specific for MND, as they were also commonly observed in other neurogenic disorders.
 Fasciculations can probably arise in various ways along the motor neuron [13]. Some of these 
ways may be normal (i.e., occur in healthy subjects as well), other are pathological. Several motor 
nerve excitability studies in patients with neurogenic disorders have shown abnormalities in sodium 
and potassium channel conductance, which are most pronounced in the distal part of the motor 
neuron in patients with ALS [14] or at the site of the lesion in MMN patients [15]. These abnormalities 
are thought to lead to an imbalance between inward sodium and outward potassium currents and, 
resulting in axonal hyperexcitability. This hyperexcitability increases the probability that an axon 
generates a spontaneous discharge (fasciculation) and also provides a plausible explanation for 
electrically evoked MDs. Such an explanation is supported by a recent study in which we showed 
that the supernormality (hyperexcitability following the refractory period of the recovery cycle) of the 
distal axon is increased in patients that show MDs but not in others [4]. Although MDs were detected 
in the clinically inconclusive patient with possible conduction block that does not affect our main 
findings of higher specificity for MDs in MND compared to fasciculations.
 Currently, information on electrically evoked MDs is scarce. These have been observed in two 
patients with ALS [16] and in some patients with unspecified neurogenic disorders [17], but their 
diagnostic value has never been investigated. Probably, the fact that MDs are so rarely mentioned in 
the literature is explained by the small probability that a trigger elicits an MD. Only 3.3% of the applied 
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triggers in this study resulted in an MD, meaning that MDs will not usually occur in neurophysiological 
recording procedures – unless long trains of stimuli are applied. Another factor is the use of single 
electrode surface EMG in conventional (surface) EMG examination, which makes it difficult to 
discriminate superimposed MUAPs and recognize MDs. HDsEMG adds spatial information, which aids 
in the recognition of individual MUAPs, and, hence, the detection of MDs. 
 In the present study half of the patients with ALS and PMA showed electrically elicited MDs whereas 
in a previous study all patients did [3]. This is probably due to our study design, which comprised 
only a single HDsEMG recording. In the previous study multiple sessions during disease progression 
were performed. The latter approach may be expected to increase the number of recorded MDs, 
because of the increased number of triggers applied [3].  However, this previous study on MDs only 
included healthy subjects besides patients with ALS and PMA, where in none of the healthy controls 
electrically elicited MDs were observed [3]. To get better insight into the specificity of distally evoked 
MDs, in the current study we extended the clinical spectrum by including patients having MND in 
their differential diagnosis. 
 In contrast to electrically evoked MDs, voluntarily activated MDs have been observed frequently 
in healthy subjects and also in neuromuscular disorders [18-20]. These MDs are thought to have a 
proximal (at the motor neuron cell body) rather than distal axonal origin [18-20]. In patients with 
MND there may, therefore, be both proximally and distally generated MDs – as there are proximally 
and distally generated fasciculations. Indeed, the frequency of voluntarily activated MDs is higher 
in patients with ALS than in healthy subjects and this has been considered an early marker of MN 
dysfunction [20]. Furthermore, spontaneous doublets have been suggested to have diagnostic value 
in routine EMG examination [21], and doublet fasciculations were more prominent in ALS when the 
disease progressed [22].
 Unfortunately, the design of our study does not allow us to draw any conclusion regarding the 
nature and specificity of proximal, voluntarily activated MDs in patients with MND. Yet, the evidence 
collected thus far, by ourselves and others, suggests that spontaneous activity (whether fasciculations 
or MDs) originating proximally can be normal whereas distally generated discharges are usually 
abnormal. There is presently no easy way to distinguish proximally from distally arising fasciculations, 
leading to a mixture of both normal and abnormal spontaneous activity on needle EMG. The two 
types of MDs however can be easily separated eliciting the MDs electrically. This likely explains the 
higher specificity of electrically elicited MDs compared to fasciculations in our study. 
 Finally, our study comprises only a relatively small number of patients. To determine the diagnostic 
accuracy of MDs more reliably, a larger set of patients is required. We are of the opinion that such an 
effort is warranted by the present findings, which show that MDs are a potentially valuable measure in 
the diagnostic phase of ALS and PMA. Currently, the HDsEMG recordings needed to detect electrically 
evoked MDs are time-consuming and require specialized equipment. However, this method may be 
helpful in making the diagnosis ALS or PMA earlier in patients that are otherwise difficult to diagnose. 
A reliable and early diagnosis will be all the more relevant when novel effective therapies become 
available. 
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Abstract
Objectives: 
To evaluate whether electrically evoked multiplet discharges (MDs) are related to severity of clinical 
deterioration in motor neuron disease (MND).
Methods: 
Stimulated high-density surface EMG (HDsEMG) recordings were performed in the thenar muscles. 
Data was collected from 31 MND patients. MDs from the HDsEMG recordings were determined at 
baseline. ALSFRS-R scores were obtained at baseline and at a maximum of sixteen weeks follow-up. 
Results: 
The presence of MUs showing MDs was associated to progressive clinical deterioration for ALSFRS-R 
(p = 0.02) and fine motor function (FMF) (p < 0.001). Patients showing higher number of MUs with 
MDs (r = 0.61, p < 0.001) as well as patients showing higher number of MDs (as percentage of applied 
stimuli) (r = 0.59, p = 0.001) corresponded with a more severe decline in their FMF.
Conclusions:
Electrically evoked MDs are associated with more severe clinical deterioration in patients with MND. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) and progressive muscular atrophy (PMA) are neurodegenerative 
motor neuron diseases (MND). The progressive loss of motor neurons leads to muscle weakness 
and eventually death. The pathophysiological mechanisms are still poorly understood, which 
makes it even more difficult to develop effective treatment strategies. There are indications that 
hyperexcitability of the motor system is a pathophysiological mechanism that almost always occurs 
during the course of MND [1, 2]. Ectopic motor unit activity in the form of fasciculations is suggested 
to be caused by excitability changes [3-5]. These hyperexcitability properties have been observed in 
the distal segments of the motor axon [4, 6, 7], but functional changes in the anterior horn cell body or 
even more central hyperexcitable motor pathways may also play a role [8-11]. It has been suggested 
that ectopic distal axonal activity in the form of multiplet discharges (MDs) after electrical stimulation 
are caused by distal pathophysiological excitability changes [12, 13]. Electrically evoked MDs can be 
reliably detected using high-density surface EMG (HDsEMG) recordings as this method aids in the 
recognition of individual motor unit action potentials (MUAPs) by adding spatial information [14, 15] 
(Fig. 1). Because the number of applied stimuli are under full control of the examiner, the procedure 
can be standardized, which enhances the quantification of MD registration. Several studies have 
shown that there is a relation between excitability properties and disease progression and prognosis 
in ALS [16, 17]. If electrically elicited MDs indeed are an expression of hyperexcitability they may have 
an important clinical relevance. Therefore, our aim was to investigate whether ectopic MU activity in 
the form of electrically elicited MDs is related to disease progression in ALS and PMA patients. 
Materials and Methods
Patients
Data was collected from 31 consecutive patients with MND obtained from previously performed and 
ongoing studies carried out at our hospital [12, 13]. These patients were classified according to the 
revised El Escorial criteria as probable or definite ALS (n = 22) or PMA (n = 9). The study protocol was 
approved by the medical ethical committee of the Erasmus MC. All patients gave written informed 
consent. 
 In these 31 patients, we performed HDsEMG recordings and determined the ALS Functional 
Rating Scale-revised (ALSFRS-R) scores. HDsEMG recordings were performed at baseline and ALSFRS-R 
scores were taken both at baseline and a maximum of sixteen weeks follow-up (mean (SD): 10.9±3.2). 
The ALSFRS-R was used to quantify disability in patients with ALS [18]. The ALSFRS-R score ranges 
from 0 (maximum disability) to 48 (normal) and can be divided into four subscores; bulbar, fine motor, 
gross motor and respiratory function. Because our HDsEMG recordings were performed in the thenar 
muscles which would more closely reflect hand muscle function, we also used the fine motor function 
(FMF) subscore for comparison (handwriting, cutting food and handling utensils, dressing and turning 
in bed and adjusting bed clothes; 4 points per item, maximal score: 16) [18]. The rate of decline in 
ALSFRS-R has been shown to be an important predictor of survival in ALS [19, 20]. 
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Figure 1. (A) A motor unit action potential (MUAP) profile recorded with the 9 x 14 electrode grid in an ALS patient over 
the thenar muscles. (B) An electrically evoked doublet of the same MU as in (A) in the consecutive stimulus. The position 
of each signal in the profile corresponds to the position in the electrode array of the electrode with which the signal was 
recorded.
Figure 2. Flow diagram and contingency tables of the decline in ALSFRS-R score and fine motor function between 
baseline and follow-up session measured in the 31 ALS and PMA patients.
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Table 1. Patient characteristics
ALS/PMA patients*
Diagnosis, ALS/PMA 22 / 9
Gender, M/F 21 / 10
Age, yrs 65 (32 – 78)
Onset to diagnosis, mnths 12.2 (7.0 – 24.4)
Survival time**, mnths 35.8 (21.4 – 50.7)
Died***, yes/no 20 / 11
ALSFRS-R, (max 48) 42.0 (40.0 – 44.0)
Fine motor function (FMF), (max 16) 14.0 (11.0 – 16.0)
Patient with MU showing MDs, yes/no 18 / 13
MUNE 107 (45 – 214)
* Values in median (25th - 75th percentile), or otherwise when indicated
** Symptom onset till death (n = 20); 
*** 15 ALS and 5 PMA patients had died
The decline in ALSFRS-R and FMF was defined as the absolute change in the scores between both 
sessions. To correlate the rate of disease progression with MD variables, the absolute change in score 
was divided by the time interval to correct for the variation in time interval between sessions. 
High-density EMG recordings and multiplet discharge registration
Detection of MDs after electrical stimulation was performed using HDEMG recordings with an 9 x 14 
electrode array attached to the skin over the thenar muscles [12]. Since the probability of eliciting an 
MD for most MUs is low, 500 stimuli (2 Hz, 0.1 ms) were applied at several sites along the median nerve 
(4 to 6 sites), and the responses were recorded. Stimulus intensity level was adjusted to activate the 
first few low-threshold MUs. This resulted in a sample of up to 20 single MUAPs per patient. For every 
subject the number of single MUAPs that elicited an MD was registered. In parallel, the number of MUs 
was estimated by dividing the maximum CMAP amplitude by the mean amplitude of the collected 
single MUAPs [14, 15]. In addition, for single MUAPs that elicited an MD, the number of stimuli when 
the MU was active and the number of stimuli that elicited an MD were registered to determine their 
proportional occurrence (Fig. 1).
Statistical analysis
Statistical analyses were performed using Matlab (R2014a: The MathWorks, Natick, MA). Normality was 
tested by the Lilliefors method. The association between the presence of electrically evoked MDs 
and any change in ALSFRS-R scores were investigated using 2x2 contingency tables. When normally 
distributed, data are presented as mean and standard deviation, otherwise as median and percentiles. 
Differences between groups were compared by t-tests or Mann-Whitney U-tests as applicable. 
Spearman’s correlation was used to assess the relation between MD variables and the change in 
ALSFRS-R scores. Differences with a p-value of < 0.05 were considered statistically significant.  
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Results
The characteristics of the 31 ALS/PMA patients at baseline session are shown in Table 1. Electrically 
elicited MDs were detected in 18 of the 31 patients with a total of 56 MUs (range 1 – 9 MUs showing 
MDs per patient). The median electrically evoked MD occurrence (as percentage of the number of 
applied stimuli) was 1.5% (IQR: 0.4% - 3.0%). There was no significant difference in number of MUs 
showing MDs between ALS and PMA patients (median: 1 vs 1, p = 0.91). Complete ALSFRS-R scores 
were available in 30 patients. The FMF scores could be obtained for both sessions in 27 patients (Fig. 2). 
We did not find any difference in ALSFRS-R score at baseline and decline of ALSFRS-R score between 
ALS and PMA patients. No relation was found between patients’ age and the number of MUs showing 
MDs. Furthermore, the time interval between sessions did not significantly differ in patients with and 
without MDs (10.9±2.9 vs 10.9±3.7 weeks, p = 0.96). At baseline MUNE was not related to ALSFRS-R 
(r = 0.21, p = 0.27). During the follow-up period, the ALS/PMA patients significantly deteriorated, as 
reflected by the absolute decline in ALSFRS-R score (median (IQR): 2 (0 – 4), p < 0.001, n = 30).
  The presence of electrically evoked MDs at baseline was associated with progressive clinical 
deterioration by ALSFRS-R (Fisher exact test, p = 0.02, n = 30, Fig. 2). Fifteen (15/17) patients in whom 
electrically evoked MDs were detected showed a decline in ALSFRS-R in the follow-up session. The 
number of MUs showing MDs at baseline showed a trend towards decline in ALSFRS-R at follow-up (r 
= 0.33, p = 0.08, n = 30). Patients who eventually showed a relatively more severe decline in ALSFRS-R 
at follow-up had a higher occurrence of MDs (as percentage of the number of applied stimuli) at 
baseline (r = 0.38, p = 0.04, n = 30). 
  Similarly, baseline presence of electrically evoked MDs was associated with progressive 
deterioration of (FMF) (Fisher exact test, p < 0.001, Fig. 2). Significant majority (13/14) of the patients 
that showed MDs had a decline in FMF between both sessions. The majority of the patients (10/13) 
without MDs showed no progressive deterioration in the functional scores. In patients with both a 
higher number of MUs showing MDs (r = 0.61, p < 0.001, n = 27) and higher occurrence of MDs (as 
percentage of number of applied stimuli, r = 0.59, p = 0.001, n = 27) at baseline, significant correlations 
with severe decline in FMF at follow-up were seen. 
Discussion
We used HDsEMG recordings to assess whether ectopic motor unit activity is related to disease 
progression in ALS and PMA patients and showed that electrically evoked MDs measured at baseline 
are associated with severity of disability progression reflected by the decline in ALSFRS-R and FMF at 
follow-up.
 In a previous small scale study it was indicated that electrically evoked MDs were likely to be 
related to clinical deterioration in MND patients averaged over several sessions in follow-up [12]. 
In this extended study we showed that already a single baseline measurement of MD variables is 
predictive of a more severe decline in disability scores in a larger patient group. 
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 Distal evoked MDs were hypothesized to be related to pathophysiological excitability changes 
[12]. A recent motor nerve excitability study demonstrated further evidence confirming this 
hypothesis where the presence of electrically evoked MDs was related to altered excitability properties 
[13]. This study showed that the same pathophysiological excitability changes are probably involved 
in generating MDs and fasciculations of distal origin. Furthermore, these distally evoked MDs were 
shown to be highly specific for MND as an early sign of lower motor neuron dysfunction [21]. These 
findings together with the association between MD variables and disease progression found in this 
study further suggest that the mechanisms leading to the generation of electrically evoked MDs is 
related to the pathophysiological changes in MND. 
 Our findings showed a significant association between the occurrence of electrically evoked 
MDs and overall disability progression (decline in ALSFRS-R). Furthermore, a trend could be observed 
between the number of MUs showing MDs and the progressive decline in ALSFRS-R, although it 
was not significant. A plausible explanation may be that the number of patients in our study could 
have been too small to show such a relation. Furthermore, the detection of electrically evoked MDs 
was restricted to the thenar muscles by the study methodology. Hence the measurements are 
likely to be more representative of fine motor skills rather than global functional skills. In addition, 
the thenar muscles are involved in the clinically often observed split hand syndrome, where they 
are relatively more affected than other muscles. This may also partly explain the lack of association 
with changes in global functional skills, although this phenomenon was not specifically assessed in 
this study. The split hand sign has been suggested to be an early feature in patients with ALS [22, 
23] and motor axonal excitability studies have shown that the motor axons innervating these hand 
muscles are differently affected [24]. Importantly, the recording of electrically evoked MDs in these 
muscles may therefore give further insight into the underlying pathophysiological mechanism of 
this phenomenon at a single motor axonal level and further insight into their relation with disease 
progression. More generally, other factors may also play a role in overall disease progression such as 
variation in site of onset and pattern of spread over body regions [25, 26]. Furthermore, excitability 
properties were suggested to change over time and therefore are different depending on the disease 
stage [4, 17]. Hence, in individual cases the results should be interpreted with caution and further 
research is required to determine if this neurophysiological finding can be used as a marker for the 
rate of disease progression in MND. Repeated MD measurements after a predefined time interval 
of for instance 1 month as well as their detection at multiple measurement sites may improve their 
ability to predict overall disease progression. 
 A limitation of the present study is that the time intervals between both sessions varied. Ideally, 
the patients should have had similar time intervals between assessments of functional scores. Some 
patients showed no change in ALSFRS-R score, probably due to a relatively slow progression, or may 
be due to a relatively short follow-up. However, the follow-up period seems to be adequate to be 
able to detect changes, because of the significant decline in function reflected by the ALSFRS-R for 
the whole patient group. There was no significant difference in the follow-up time between patients 
with and without MDs, and hence this factor would have a negligible effect on our findings. To relate 
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MD variables to disease progression, the results were corrected for the time interval, assuming a linear 
disease progression as reflected by the ALSFRS-R score. Although it is difficult to determine how this 
assumption is met, various studies consider a linear disease progression in ALS to be an adequate 
estimate [27-30]. 
 In conclusion, the presence of electrically evoked MDs at baseline measurement is associated 
with a more severe clinical deterioration reflected by the disability scores at follow-up. The detection 
of electrically evoked MDs makes it possible to non-invasively examine and selectively investigate 
excitability properties at the distal part of the motor axon. A larger set of patients should further 
evaluate the prognostic value of electrically evoked MDs to predict clinical deterioration and their 
usefulness in clinical practice. This study of MDs seems to be a suitable tool for further research and 
larger clinically oriented studies.
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In the previous chapters, the application of several advanced surface EMG techniques in a research 
setting and in clinical practice in patients with motor neuron disease (MND) has been explored. The 
possibilities offered by these techniques could eventually support the diagnostic process and give a 
more objective insight into the course of the disease, and could potentially facilitate the evaluation of 
novel therapies. For this purpose, this thesis predominantly focused on fasciculation potentials (FPs), a 
clinical hallmark in MND, and multiplet discharges (MDs) after electrical stimulation. These two types 
of ectopic activity of individual motor units (MUs) are thought to be an expression of affected MUs. 
Therefore, they may have diagnostic and prognostic relevance. The main goals of this thesis were the 
following: 
1) To evaluate and further improve the available research methods for the non-invasive study of 
individual motor units.
2) To develop neurophysiological markers of clinical relevance in individual patients with ALS and 
PMA, which can be obtained with these surface EMG methods.
3) To clarify the pathophysiological and clinical significance of FPs and electrically evoked MDs. 
The most important findings described in this thesis and the formulated goals will be discussed 
here, based on their methodological and pathophysiological aspects. Subsequently, the clinical 
implications will be evaluated, followed by recommendations for future studies. 
Methodological aspects
The first goal of this thesis was covered through the development of an automated method to 
quantify the CMAP scan pattern in a single marker, D50 (Chapter 2). The automated method mitigates 
susceptibility to operator-related variability in the current manual procedure and can therefore 
potentially improve the utility of the CMAP scan as a follow-up tool [1]. This marker can be easily 
determined, so the results can become directly available to the clinician during electrodiagnostic 
examination.
  By relating D50 to MU loss, the second goal of this thesis was realized. D50 was found to be 
sensitive to MU loss and reinnervation, which is already commonly present in the diagnostic phase in 
patients with MND. The sensitivity of D50 to MU loss and reinnervation decreases when there are more 
than approximately 80 MUs innervating a muscle, because then a smooth, gradually increasing CMAP 
scan pattern becomes visible. This smoothing effect is caused by the large number of possibilities 
in terms of active MUs at a particular stimulus intensity. This effect is also encountered by more 
computationally intensive methods [2-4]. Still, the CMAP scan can be applied in other conditions such 
as Guillain-Barré, because it contains useful clinical information on axonal excitability [5, 6]. 
  Practical factors remain important for the quality of the CMAP scan (and thereby the accurate 
assessment of D50), such as avoiding redundant applied triggers, instructing patients to relax their 
muscles, and minimizing movement artefacts. Alternative stimuli protocols are interesting options 
to explore for the further improvement of the CMAP scan as a diagnostic instrument and follow-up 
tool. In this way, the CMAP scan could be made more sensitive to MU loss, reinnervation, and possibly 
also for measuring higher number of MUs. The successfully implemented CMAP scan simulation 
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model and motor unit number estimation (MUNE) using high-density surface EMG (HDsEMG) can 
provide useful insights into the above approaches. The effect of alternative protocols on D50 and 
other parameters need further exploration. 
A longitudinal study to track changes in individual MUs, referred to as motor unit tracking, may 
provide novel pathophysiological information on disease progression in patients with MND [7]. In an 
identified MU action potential (MUAP) profile, changes can occur between sessions. These can result 
from either suboptimal reproducibility, such as replacement error of the high-density electrode grid, 
or from pathophysiological changes. Hence, the further repositioning errors can be reduced, the finer 
the changes that can be reliably ascribed to disease progression. 
 The first goal of this thesis was achieved by illustrating the feasibility of correcting HDsEMG 
electrode grid displacement errors (Chapter 3). Yet, other factors need to be taken into account as well 
(e.g. adopting the same hand position), which requires standardization of the set-up. Even though, 
motor unit tracking is still laborious and currently unsuitable for general clinical practice, it remains 
a promising research tool. The automated adjustment for correcting electrode grid replacement 
errors, as described in Chapter 3, may help to improve this research tool for follow-up studies of 
neuromuscular disorders. 
The clinical relevance of fasciculation potentials (FPs) is underlined by the fact that they are 
incorporated in the latest electrodiagnostic criteria for ALS [8]. FPs are the spontaneous activity of 
single MUs, and they are a characteristic, but nonspecific feature of MND. During EMG examination, 
FPs are most commonly observed as isolated discharges [9]. However, in routine electrodiagnostics, 
there are no quantitative criteria that define an MU discharge as a pathological discharge (FP). 
Therefore, the identification of FPs relies on operator’s experience, which implies that an element of 
subjectivity remains present.  
 The findings in Chapter 4 covered the first goal of this thesis through the development of a 
potential clinically relevant method for objective quantification of MU discharges. The results 
revealed that a pathological discharge cannot be identified based on information from only a single 
MU. However, we obtained an improved identification of patients with MND compared to healthy 
controls when using a new marker that incorporates the activity of multiple MUs showing isolated 
discharges in a specific time interval. This implies that the presence of a few sporadic FPs (originating 
from a single MU) itself should not be considered an abnormality. Only when the FPs originate from 
multiple MUs a link can be made to MND as underlying pathology. These findings correspond with 
the clinically often observed abundant nature of fasciculations in patients with MND. Considering the 
impact on the diagnosis of this finding, it must be noted that for the diagnosis of MND other signs 
(muscle weakness / atrophy, fibrillations and giant MUAPs) are very important. However, in the early 
phase of the disease, FPs might be the only feature present, which makes it more difficult to deduce 
their pathological significance [10]. This difficulty can then potentially be mitigated using a marker 
that objectifies the quantity of FPs (discharge pattern of multiple MUs).
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 As a step towards the second goal of this thesis, this marker may therefore be a useful feature 
in the diagnostic phase of MND, or in clinically still unaffected muscles by assessing the number 
of different MUs from which the spontaneous activity originate. Future clinically oriented studies 
should determine its optimal discriminative value, because this will depend on the muscle under 
investigation [11, 12], the applied recording technique and recording duration. 
Pathophysiological aspects
The pathophysiological mechanisms in MND are still not well understood. Altered excitability properties 
of motor axons have been suggested to be the underlying pathophysiological mechanism in MND 
that would lead to the occurrence of fasciculations [13-15]. Recently, electrically evoked multiplet 
discharges (MDs) by means of HDsEMG were introduced as an approach to examine the distal part 
of single motor neurons in patients with MND [16]. Currently, little information on electrically evoked 
MDs is available [17, 18]. They were hypothesized to be related to pathophysiological excitability 
changes. However such a relation was not established. A better understanding of the etiology of MDs 
is required to bring them closer to clinical use.
 Regarding the third goal of this thesis, the findings in Chapter 5 confirm that patients showing 
MDs had altered axonal excitability properties that were similar to changes observed in other 
excitability studies addressing fasciculations [14, 15, 19-21]. Electrically evoked MDs were thought to 
originate at the terminal branches of the axon [16], just like distal fasciculations [22, 23]. Our findings 
suggest there is a common mechanism involved behind the generation of distal fasciculations and 
electrically evoked MDs in MND. The study described in Chapter 5 demonstrates that excitability 
properties in single MUs can be evaluated by detecting electrically evoked MDs by means of HDsEMG 
in a controlled and objective manner. 
Diagnostic relevance of electrically evoked multiplet discharges 
To clarify the diagnostic significance of electrically evoked MDs patients, we examined patients with a 
suspected diagnosis of MND (Chapter 6). The third goal of this thesis was achieved through this study 
by establishing the diagnostic relevance of electrically evoked MDs for MND. The findings indicated 
that they were more specific than FPs. 
  The location where MDs arise appears to be an important factor in explaining their higher specificity 
for abnormal motor axonal function. FPs can arise from various locations [15, 22, 24-27], where some 
of them are normal, because they also occur in healthy subjects ([11, 28, 29], Chapter 4), while others 
are pathological. Voluntarily activated MDs (not electrically evoked) have been commonly observed in 
healthy subjects and also in various other neuromuscular disorders [30-32]. These voluntarily activated 
MDs are thought to originate proximally at the motor neuron cell body. Proximal MDs can also occur 
due to subtle ballistic contractions [31, 33, 34]. Hence, in MND there could be a mixture of both distally 
and proximally generated MDs, just as there are proximally and distally generated fasciculations. By 
evoking MDs electrically, the distal and proximal types can be separated. Our findings, and findings 
by others, suggest that MU discharges (FPs or MDs) that originate proximally are usually normal 
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(physiological), whereas distally generated discharges are usually abnormal [35, 36]. This may explain 
the higher specificity of electrically elicited MDs compared to FPs in our study.  
 It must be noted that the occurrence of FPs varies between muscles [11], which may also be 
the case for electrically evoked MDs. Therefore, the specificity of electrically evoked MDs in other 
muscles is currently unclear. Theoretically, there may be other physiological mechanisms and disease 
processes with similar changes in the membrane potential that could cause this type of discharge, 
indicating that they may also represent different phenomena [37-39]. Nonetheless, it can be argued 
that in the given clinical context, electrically evoked MDs are of diagnostic relevance for patients with 
ALS and PMA as we observed in our study (Chapter 6).
Ectopic motor unit activity: an early expression of the beginning of the end? 
It has been shown that FPs have prognostic relevance [40, 41]. FPs have been suggested to be an 
early manifestation of progressive lower motor neuron dysfunction [35]. With regard to the third goal 
of this thesis, the findings in Chapter 4 suggest that pathophysiological information can be deduced 
from spontaneous MU discharges when they originate from multiple MUs showing such discharges. 
Sporadic MU discharges may have a normal physiological origin [42], but their exaggerated presence 
(originating from multiple MUs) may be more likely due to an underlying pathology, which could be 
induced by pathophysiological excitability changes [14, 15]. How the abundance of spontaneous MU 
discharges evolves during disease progression remains to be defined. Ectopic MU activity in the form 
of electrically evoked MDs has been associated with MU loss and clinical deterioration in patients 
with MND [16]. The findings in Chapter 7 showed that the number of MDs at a baseline session in 
patients with ALS/PMA was related to the rate of functional decline. This further suggests that distally 
evoked MDs provide an indication of pathophysiological excitability changes. Whether the excitability 
changes are a result or a cause of axonal degeneration currently remains unclear. 
 Altered excitability properties are likely the mechanism behind FPs and electrically evoked 
MDs. More generally, in patients with MND, there are several indications that hyperexcitability is 
a pathophysiological mechanism that almost always occurs during the course of the disease [43, 
44]. The interspike intervals of distally evoked MDs correspond with the supernormality period and 
the presence of electrically evoked MDs is related to increased supernormality (Chapter 5). Despite 
the fact that ion channel expression may differ at the terminal branches, potassium conductance 
impairment seems to be a likely explanation for the increased supernormality [14, 15, 19, 21]. In animal 
studies, blocking of presynaptic potassium channels located at the nerve terminal branches has 
shown to lead to repetitive discharges after a single electrical trigger [45, 46]. When this observation 
can be extrapolated to humans, this may further point towards reduced potassium conductance. 
Interestingly, in disorders characterized by potassium channel dysfunction, the presence of many 
(spontaneous) MDs is noteworthy [39, 47]. Preliminary findings in a motor unit tracking study in MND 
showed increasing occurrence of MDs in individual MUs over time (unpublished data). This may 
indicate ongoing potassium conductance impairment related to motor neuron degeneration.  
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 Despite the probable relation described above, the mechanisms of motor neuron death in MND 
are still far from fully understood and there may be various other degenerative pathways. Our results 
demonstrate that by studying ectopic MU activity in the form of FPs and electrically evoked MDs, a 
contribution can be made towards further unravelling the pathophysiological mechanisms in MND 
(Chapter 4, 5, 6, 7). 
Clinical implications 
Diagnostic phase
Because of the absence of a specific biomarker for MND, any measure that could facilitate the 
diagnosis of MND would fill a large clinical gap. The CMAP scan may be a useful tool in the diagnostic 
phase, because the novel marker, D50, can detect underlying neurogenic abnormalities. Therefore, 
it can be used as a sensitive and objective assessment in addition to the clinical symptoms (muscle 
weakness, muscle atrophy). In this way, the CMAP scan provides information that complements 
routine NCS and needle EMG findings. Needle EMG will still be required as a diagnostic test because 
it can detect neurogenic changes and spontaneous muscle fiber activity not accessible with surface 
EMG. However, needle EMG may not always be necessary in some clinical situations, and in those 
cases, the CMAP scan can potentially be a useful alternative. The CMAP scan has the advantage of 
activating all MUs, while needle EMG relies on a limited sample of MUs in a muscle.
 Future research is required to determine the sensitivity of the CMAP scan to detect neurogenic 
abnormalities in comparison with needle EMG. Owing to its non-invasive nature and the relatively 
easy procedure, the CMAP scan can be more readily applied than needle EMG, e.g, in children, and in 
longitudinal studies [48]. 
In the Awaji diagnostic criteria of ALS, equal weight is given to clinical and electrophysiological findings 
in defining the presence of lower motor neuron dysfunction [8]. In these criteria, the presence of FPs 
is considered equivalent to fibrillations and positive sharp waves [8]. The findings in Chapter 4 add 
to this criterion and imply that in addition to solely assessing presence of FPs, supplemental relevant 
information can be obtained by assessing the number of different MUs from which they originate. 
This especially can be helpful in the early stage of MND, or in clinically unaffected muscles, where FPs 
might be the only feature present. This information can potentially be used to aid in differentiating 
MND from other disorders.
 Initial implementation of our quantitative method requires incorporation into routine needle 
EMG software that includes an MU analysis program [49, 50]. Then, further clinical investigations 
are needed to establish adequate norms for pathology when our method is used with needle EMG. 
Finally, a next step could be to relate the quantity of FPs (originating from multiple MUs) in a specified 
time interval to the diagnosis.
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In addition, electrically evoked MDs were demonstrated to be of diagnostic relevance for patients with 
MND. The findings indicated that they were more specific than FPs (Chapter 6). Hence, electrically 
evoked MDs may fit into the existing diagnostic criteria as an additional electrophysiological sign. 
Even though, electrically evoked MDs are obtained from a single nerve, they can provide useful 
clinical information in the clinical context of patients with a suspected diagnosis of MND.
   Currently, detecting electrically evoked MDs requires relatively laborious HDsEMG recordings and 
analysis, which makes it not directly applicable in clinical practice. Future studies should concentrate 
on modifying the recordings and analysis to mitigate this laborious procedure. An earlier diagnosis 
may improve patients’ perspectives, especially when novel effective therapies finally become available, 
and because it may help to reduce stress and uncertainty for patients and their families.
Disease progression and prognosis
For evaluating the effectiveness of novel therapies, an accurate, reproducible marker is required that 
can monitor disease progression. Motor unit number estimation (MUNE) has been shown to be a more 
sensitive marker of disease progression than muscle force measurements, or ALS questionnaires [51-53]. 
The CMAP scan can be performed quickly, is well tolerated by patients, and has shown promising 
results in monitoring disease progression in MND [1, 54-56]. The automated method described in 
Chapter 2 may therefore be preferable to existing MUNE techniques, because it can be performed 
quickly and easily. Additionally, the automated method can be implemented in routine EMG software 
and the computational effort is small. 
Various studies have shown that the widespread presence of fasciculations in multiple body regions is 
of prognostic significance [40, 41]. Applying the quantitative method of identifying FPs, as described 
in Chapter 4, allows FPs to be systematically evaluated at an individual MU level and related to disease 
progression and prognosis. In addition, a longitudinal study that combines ectopic MU activity, motor 
nerve excitability testing and MUNE has been performed, and the measurements are ready to be 
analyzed. This study can potentially give important information on how these various features relate 
to each other during the course of the disease. For future longitudinal studies, it seems to be adequate 
to perform four follow-up sessions, considering the impact of such studies on patients. Follow-up 
sessions should be combined as much as possible with the regular visits to the hospital.
The findings described in Chapter 7 showed the relation between electrically evoked MDs and more 
severe decline in fine motor skills. Owing to the variability between patients, these results should 
be interpreted with caution in individual patients. Therefore, a larger study should evaluate whether 
electrically evoked MDs could be of help in order to better inform patients about their increased risk 
of decline in fine motor functions, such as hand skills. Further down the line, they might also be used 
in combination with clinical signs, such as muscle weakness and atrophy, in order to guide clinicians 
regarding further treatment. 
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Concluding remarks 
For electrodiagnostic examination of MND, a proper evaluation of individual MUs is required. This thesis 
has provided novel pathophysiological and clinical insights into MND at the level of individual MUs. 
The applied surface EMG techniques and enhanced methodologies yielded novel and complementary 
diagnostic and prognostic information that could not reliably be obtained with current routine 
techniques. Furthermore, the HDsEMG system can be applied as a useful reference tool to existing 
EMG techniques and new EMG techniques. The findings in this thesis warrant further exploration of 
these techniques, but their demonstrated utility outweighs the challenges of data analysis and data 
acquisition for their eventual integration. In the field of electrodiagnostic examination, there is an 
increasing interest in the use of surface EMG, because it is more comfortable for patients than routine 
needle EMG [57]. This thesis forms a crucial basis towards clinical application of surface EMG in the 
field of clinical neurophysiology. This could help to improve the clinical process and the development 
of novel therapies for patients with ALS and PMA.
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Future perspectives 
In this thesis, several surface EMG methods have been applied and the results showed promising 
avenues for future studies. This presents opportunities for improving the diagnosis and clinical 
management of MND. Future steps can be made in the following directions:
Before the CMAP scan can be widely implemented in clinical practice, normative data need to be 
collected (D50, and potentially other future variables) in multiple muscles. 
 The split-hand syndrome has been shown to be a useful diagnostic sign in patients with ALS [58, 
59]. The diagnosis of ALS can potentially be further facilitated by applying the CMAP scan to the split-
hand muscles. 
  A longitudinal study in multiple muscles (e.g. split-hand) can determine the usefulness of 
the CMAP scan in monitoring the rate of disease progression in MND for phase II clinical trials. A 
comparison with other measures (neurophysiological index [60], ALSFRS-R) is recommended. 
Although implementation of HDsEMG on a wide scale is currently still limited due to the specific 
equipment and software required, the following steps may help to make it a more accepted technique 
in basic research and clinically oriented studies. 
  First, the high specificity of electrically evoked MDs in patients with MND described in Chapter 6 
warrants ongoing research in this direction. This may be in the form of a study to further investigate 
the diagnostic value and applicability of this approach in current clinical practice. A close cooperation 
with specialized ALS centers is recommended to collect a sufficiently large group of patients and 
controls. Such a study should also be able to clarify the prognostic value of electrically evoked MDs. 
 Another way forward would be to undertake the technical challenges involved in the HDsEMG 
technique [61, 62]. Data analysis software of the procedures for MUNE, motor unit tracking, and 
spontaneous/voluntary MU activity can be further refined to reduce time for data analysis, and to 
enhance the detection of clinically relevant variables, e.g. the widespread presence of fasciculations. 
Although it is not without difficulties, the approach described in Chapter 4 can potentially support 
the clinical examination, because it is a more sensitive and objective screening method in measuring 
spontaneous activity in muscles.
A small-scale motor unit tracking study, in conjunction with motor nerve excitability testing (applied 
on single MUs [42, 63]), could be applied in patients with MND versus healthy controls, or in patients 
with MND in multiple follow-up sessions. This way, the changes of MU properties may reveal novel 
pathophysiological insights into the disease process in individual MUs. If so, this may provide a better 
understanding of the processes related to MU degeneration.
General discussion 129
8
The promising findings of this thesis provide a basis for, and will hopefully stimulate, future 
methodologically, pathophysiologically and clinically oriented studies of surface EMG in 
electrodiagnostics. The combined effort into these three areas is required to bring surface EMG closer 
to clinical application. This thesis offers tools along this path, which may help us to reach the ultimate 
goal: to improve quality of life and life expectancy in patients with MND.
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Summary
Motor neuron disease (MND) is a severe and incurable disease, characterized by the progressive loss 
of motor neurons that control voluntary contraction of the muscles. The most common variants of 
MND are amyotrophic lateral sclerosis (ALS) and progressive muscular atrophy (PMA). Owing to the 
relentless course of the disease, an early and accurate diagnosis is important especially when new 
and effective drug therapies become available. Evaluating the effectiveness of novel therapies (to 
ultimately improve quality of life and life expectancy) requires an accurate and reproducible marker 
that can monitor disease progression. For this purpose, the smallest functional element of the 
neuromuscular system for voluntary muscle contraction is studied, known as the motor unit (MU). 
In MND, these functional components are affected, which is why evaluating the functioning of MUs 
is an important aspect in the electrodiagnostic examination. As described in Chapter 1, current 
standard electromyographic (EMG) techniques have their limitations, especially when measuring 
at the level of individual MUs. These limitations can partly be resolved by more advanced surface 
EMG techniques. The possibilities offered by the advanced surface EMG techniques may eventually 
support the diagnostic process and give a more objective insight into the course of the disease. 
This thesis predominantly focused on fasciculation potentials (FPs), a clinical hallmark in MND, and 
multiplet discharges (MDs) after electrical stimulation. These two types of ectopic activity of individual 
MUs are thought to be an expression of a diseased state of MUs due to MND. Therefore, they may 
have diagnostic and prognostic relevance. The research described in this thesis has the following 
aims: (1) to evaluate and further improve the available research methods for the non-invasive study of 
individual MUs, (2) to develop neurophysiological markers of clinical relevance in individual  patients 
with ALS and PMA, which can be obtained with these surface EMG methods, and (3) to clarify the 
pathophysiological and clinical significance of FPs and electrically evoked MDs.
One of the surface EMG methods that needed to be further developed was the compound muscle 
action potential (CMAP) scan, which reflects the successive activation of all MUs in a muscle. The 
CMAP scan provides clinical information on MU size, MU number and axonal excitability that 
complements the electrodiagnostic findings obtained with routine motor nerve conduction studies 
and needle EMG. Currently, a manual procedure is applied to extract the clinical information from 
the CMAP scan, which is time-consuming and susceptible to operator-related variability. In order to 
overcome these issues, an automated method is described in Chapter 2 that has been developed 
to objectively quantify the largest discontinuities (visual as gaps) in the CMAP scan. This has resulted 
in a novel neurophysiological marker, D50, which was applied to CMAP scans originating from 
healthy subjects and patients with a variety of neuromuscular disorders. This marker was shown 
to be sensitive to MU loss and reinnervation, which are processes highly consistent with ALS and 
PMA. Therefore, it is potentially useful to monitor disease progression in patients with MND. Due to 
the small computational effort in determining D50, the results can become directly available to the 
clinician during the electrodiagnostic examination. 
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Another research method, motor unit tracking using high-density surface EMG (HDsEMG), has 
been introduced as a novel approach for monitoring individual MUs over time. This may yield 
new information on pathophysiological changes of the disease process on individual MU level. 
At present, motor unit tracking is performed without correcting for displacement of the HDsEMG 
electrode array between recording sessions. To achieve this, we developed an algorithm to correct 
for HDsEMG electrode displacement errors in motor unit tracking (Chapter 3). This proof-of-concept 
study in healthy subjects shows that automated correction is feasible when identifying MU action 
potentials between the measurement sessions. When incorporated in the software, the automated 
correction may improve the certainty with which changes in MU action potentials can be ascribed 
to pathophysiological changes. This will allow motor unit tracking for follow-up studies with a higher 
precision than currently possible. 
FPs are incorporated in the latest electrodiagnostic criteria for ALS, but they can also be observed in 
healthy subjects. They are commonly detected as isolated single MU discharges. However, in routine 
electrodiagnostics, the identification of FPs relies on subjective assessment. Therefore, in Chapter 4 
a novel objective approach was introduced that characterizes MU discharges in a muscle at rest. 
In the automated approach applied to HDsEMG recordings in patients with ALS and PMA and 
healthy controls, MU discharges were quantified based on the interspike interval before and after 
each discharge. This approach revealed that, based on the discharge pattern of single MUs, it was 
actually not possible to identify pathological discharge patterns. Considering the common clinically 
observed abundance of fasciculations, a new marker was determined that takes into account the 
activity of multiple MUs showing isolated discharges in a specific time interval. By using this marker, 
we obtained an improved identification of patients with MND compared to healthy controls. This 
can be especially helpful in clinically unaffected muscles, where fasciculations might be the only 
feature present. Furthermore, when this marker is implemented in routine needle EMG software, it 
may serve as a more objective approach to determine the level of spontaneous MU activity during 
electrodiagnostic examination. 
Electrically evoked MDs using HDsEMG have been recently applied to study the distal involvement 
of the motor neuron in patients with ALS and PMA. These MDs were thought to be related to 
pathophysiological excitability changes. The findings described in Chapter 5 confirm this relation 
between the presence of electrically evoked MDs and altered motor axonal excitability properties 
in patients with suspected MND. Moreover, the excitability changes were similar to changes 
observed in previous studies addressing fasciculations in patients with ALS. This implies a common 
pathophysiological mechanism for electrically evoked MDs and distal fasciculations. These MDs 
may therefore have similar diagnostic significance as FPs in patients with MND. To investigate 
this, a diagnostic study was performed in patients with suspected MND (Chapter 6). The results 
demonstrated that electrically evoked MDs are a potentially valuable measure in the diagnostic 
phase of patients with ALS and PMA. Furthermore, the findings indicated that they are an even more 
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specific electrophysiological sign of lower motor neuron dysfunction than FPs. A subsequent study 
was performed to assess whether electrically evoked MDs were related to the disease progression in 
patients with ALS and PMA (Chapter 7). The findings showed that electrically evoked MDs in patients 
with ALS and PMA are associated with more severe clinical deterioration. This suggests that the 
mechanism that promotes the occurrence of electrically evoked MDs is related to pathophysiological 
changes. Finally, in Chapter 8 the main findings of this thesis are discussed, as well as directions for 
future work. This thesis has led to clinically relevant insights for patients with MND, which cannot 
be obtained with routine EMG techniques. Several interesting approaches and challenges remain 
present to further improve the applied surface EMG methods as a research tool and to bring them 
closer to a hopefully wider clinical application. 
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Samenvatting
“Motor neuron aandoeningen” zijn een categorie van zenuwaandoeningen die in het Engels beter 
bekend staat onder de term “motor neuron disease” (afgekort MND). Deze ernstige en ongeneeslijke 
aandoeningen worden gekenmerkt door het progressieve verlies van motorische neuronen die 
zorgen voor de vrijwillige aanspanning van de spieren. De meest voorkomende varianten van MND 
zijn amyotrofische lateraal sclerose (ALS) en progressieve musculaire atrofie (PMA). Vanwege het 
meedogenloze ziekteverloop is het belangrijk om in een vroeg stadium een nauwkeurige diagnose 
te stellen. Dit is vooral van belang wanneer er effectieve medicijnen beschikbaar komen. Voor het 
evalueren van de effectiviteit van nieuwe therapieën (om uiteindelijk kwaliteit van leven en de 
levensverwachting te verbeteren) is er een nauwkeurige, reproduceerbare marker nodig om het 
ziekteverloop te meten. Hiervoor is de kleinste functionele eenheid in het neuromusculaire systeem 
voor de vrijwillige aanspanning van een spier bestudeerd, die ook wel de motorische eenheid (“motor 
unit” in het Engels, afgekort MU) wordt genoemd. Individuele MUs zijn belangrijke functionele 
componenten die aangedaan zijn door MND. Vandaar ook dat de evaluatie van het functioneren 
van MUs een belangrijk onderdeel is bij het elektrodiagnostisch onderzoek. Zoals beschreven in 
Hoofdstuk 1, hebben de huidige elektromyografische (EMG) technieken die gebruikt worden bij het 
elektrodiagnostisch onderzoek enkele nadelen, vooral bij het meten op het niveau van individuele 
MUs. Deze nadelen kunnen door meer geavanceerde oppervlakte-EMG-technieken (“surface EMG” 
in het Engels, afgekort sEMG) gedeeltelijk verholpen worden. Deze sEMG-technieken hebben als 
mogelijkheid om uiteindelijk te helpen bij het stellen van een diagnose en het ziekteverloop in 
kaart te brengen. Dit proefschrift is grotendeels gericht op het meten van fasciculatiepotentialen 
(“fasciculation potentials” in het Engels, afgekort FPs), een belangrijk klinisch kenmerk in MND, en 
repetitieve ontladingen (“multiplet discharges” in het Engels, afgekort MDs) na elektrische stimulatie. 
Deze twee typen van ectopische activiteit van individuele MUs worden gezien als een uiting van 
zieke, aangedane MUs als gevolg van MND. Daarom kunnen ze mogelijk ook van diagnostische en 
prognostische waarde zijn. Het onderzoek beschreven in dit proefschrift heeft de volgende doelen: 
(1) het evalueren en verder verbeteren van de beschikbare onderzoeksmethoden om op niet-
invasieve wijze individuele MUs te kunnen bestuderen, (2) het ontwikkelen van klinisch relevante 
neurofysiologische markers bij individuele patiënten met ALS en PMA, die kunnen worden verkregen 
met deze sEMG-methoden, en (3) het verduidelijken van de pathofysiologische en klinische betekenis 
van FPs en MDs na elektrische stimulatie.
Eén van die sEMG-technieken die verder ontwikkeld moest worden, was de “compound muscle 
action potential” (CMAP) scan. Hierin worden door elektrische stimulatie van een motorische zenuw 
achtereenvolgens alle MUs in een spier geactiveerd. De CMAP-scan geeft klinische informatie over 
de grootte van MUs, het aantal MUs en de prikkelbaarheid van de zenuw. Dit is een waardevolle 
aanvulling op de bevindingen die worden verkregen tijdens het motorische geleidingsonderzoek 
en het naald-EMG. Op dit moment wordt er een handmatige methode gebruikt om de klinische 
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informatie uit de CMAP-scan te halen. Dit proces is tijdrovend en gevoelig voor variabiliteit tussen 
gebruikers. Om deze tekortkomingen te verhelpen, wordt er in Hoofdstuk 2 een automatische 
methode beschreven, waarbij de grootste discontinuïteiten (zichtbaar als stappen) in de CMAP-
scan nu objectief gekwantificeerd worden. Dit heeft geresulteerd in een nieuwe neurofysiologische 
marker, D50, die toegepast is op CMAP-scans van zowel gezonde proefpersonen als patiënten met 
verschillende neuromusculaire aandoeningen. Daarbij hebben we aangetoond dat deze marker 
gevoelig is voor MU-verlies en reinnervatie. Deze processen zijn allebei duidelijk aanwezig bij 
patiënten met ALS en PMA. Daarom is deze methode mogelijk ook te gebruiken bij het meten van 
het ziekteverloop bij patiënten met MND. Het bepalen van D50 vergt weinig rekenkracht, dus het 
resultaat kan direct beschikbaar komen voor de arts tijdens het elektrodiagnostisch onderzoek.
Een andere methode, genaamd ‘motor unit tracking’ met behulp van ‘high-density’ oppervlakte-
EMG (“high-density surface EMG” in het Engels, afgekort HDsEMG) is onlangs geïntroduceerd om 
individuele MUs in de tijd te volgen. Dit kan mogelijk informatie opleveren over de pathofysiologische 
veranderingen van het ziekteproces op het niveau van een individuele MU. Op dit moment wordt 
motor unit tracking uitgevoerd zonder rekening te houden met verplaatsingen van het HDsEMG-
elektrodenmatje tussen meetsessies. Om dit te verhelpen, hebben we een algoritme ontwikkeld 
waardoor verplaatsingsfouten van het HDsEMG-elektrodenmatje bij motor unit tracking worden 
gecorrigeerd (Hoofdstuk 3). Uit dit ‘proof-of-concept’-onderzoek bij gezonde proefpersonen blijkt 
dat automatische correctie mogelijk is bij het identificeren van specifieke MU-actiepotentialen 
die gevonden zijn tijdens meerdere metingen. Wanneer deze methode wordt opgenomen in de 
software voor de analyse van motor unit tracking, kunnen hiermee mogelijk de veranderingen in 
de MU-actiepotentialen met grotere betrouwbaarheid toegeschreven worden aan werkelijke 
pathofysiologische veranderingen. Hierdoor kan motor unit tracking in vervolgonderzoek mogelijk 
met een hogere nauwkeurigheid worden uitgevoerd dan momenteel mogelijk is. 
FPs zijn opgenomen in de meest recente elektrodiagnostische criteria voor ALS, maar ze worden 
ook gezien bij gezonde proefpersonen. Vaak worden ze gedetecteerd als enkele, geïsoleerde 
MU-ontladingen, maar uiteindelijk worden FPs in het elektrodiagnostisch onderzoek op een 
subjectieve manier geïdentificeerd. Daarom wordt er in Hoofdstuk 4 een nieuwe objectieve manier 
geïntroduceerd voor het karakteriseren van MU-ontladingen in een spier in rust. In de automatische 
analyse, toegepast op HDsEMG-metingen bij patiënten met ALS en PMA en gezonde proefpersonen, 
worden MU-ontladingen gekwantificeerd op basis van de tijdsintervallen voor en na elke ontlading. 
Echter, uit de automatische analyse bleek dat het op basis van enkele MUs niet mogelijk was om een 
pathologisch ontladingspatroon te identificeren. Aangezien er tijdens klinisch onderzoek vaak een 
overvloed aan fasciculaties wordt gevonden, werd er een nieuwe marker bepaald die rekening houdt 
met de activiteit van meerdere MUs met geïsoleerde ontladingen in een specifiek tijdsinterval. Met 
deze marker bleken patiënten met MND beter te kunnen worden geïdentificeerd in vergelijking met 
gezonde proefpersonen. Dit kan vooral nuttig zijn in klinisch niet aangedane spieren waarin alleen 
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nog fasciculaties waargenomen worden. Als deze marker tevens in standaard naald-EMG-software 
wordt geïmplementeerd, zou deze mogelijk een objectievere manier zijn om de mate van spontane 
MU-activiteit te bepalen tijdens het elektrodiagnostisch onderzoek. 
Elektrisch geactiveerde MDs zijn onlangs toegepast om het distale gedeelte van het motorneuron 
te bestuderen bij patiënten met ALS en PMA. Men vermoedde dat deze MDs gerelateerd waren aan 
pathofysiologische veranderingen in de prikkelbaarheid van de zenuw. De bevindingen in Hoofdstuk 5 
bevestigen dat bij patiënten met een klinische verdenking op MND de aanwezigheid van elektrisch 
geactiveerde MDs gerelateerd is aan de veranderde eigenschappen van de prikkelbaarheid van 
zenuwvezels. Bovendien waren de veranderingen in prikkelbaarheid vergelijkbaar met veranderingen 
waargenomen bij eerdere onderzoeken naar fasciculaties bij patiënten met ALS. Dit wijst op een 
gemeenschappelijk pathofysiologisch mechanisme voor elektrisch geactiveerde MDs en distale 
fasciculaties. Deze MDs hebben daarom ook mogelijk dezelfde diagnostische betekenis als FPs. 
Om dit te onderzoeken, is er een diagnostische studie uitgevoerd bij patiënten met een klinische 
verdenking van MND (Hoofdstuk 6). De resultaten toonden aan dat elektrisch geactiveerde MDs 
in de diagnostische fase bij patiënten met ALS en PMA een potentieel waardevolle maat zijn. Uit de 
bevindingen bleek tevens dat ze een specifieker elektrofysiologisch kenmerk zijn voor aantasting van 
het perifeer motorisch neuron dan FPs. Een volgende studie was uitgevoerd om na te gaan of deze 
MDs ook gerelateerd zijn aan het ziekteverloop bij patiënten met ALS en PMA (Hoofdstuk 7). Uit de 
bevindingen blijkt dat elektrisch geactiveerde MDs bij patiënten met ALS en PMA samenhangen met 
een sterkere klinische achteruitgang. Dit doet vermoeden dat het mechanisme dat zorgt voor het 
optreden van elektrisch geactiveerde MDs gerelateerd is aan pathofysiologische veranderingen. Tot 
slot worden in Hoofdstuk 8 de belangrijkste bevindingen en richtingen voor toekomstig onderzoek 
besproken. Dit proefschrift heeft geleid tot klinisch relevante inzichten bij patiënten met ALS en 
PMA, die niet kunnen worden verkregen met de huidige EMG-technieken. Er blijven verschillende 
interessante opties en uitdagingen over voor de verdere verbetering van de toegepaste sEMG-
methoden als onderzoeksinstrument en van de methoden zelf,  waardoor deze methoden dichter bij 
een hopelijk bredere klinische toepassing komen.
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AANEM  American Association of Neuromuscular & Electrodiagnostic Medicine
ALS  amyotrophic lateral sclerosis
ALSFRS-R  amyotrophic lateral sclerosis functional rating scale – revised
APB  abductor pollicis brevis
AUC  area under the curve 
BFS  benign fasciculation syndrome
CI  confidence interval
CMAP  compound muscle action potential
CMC  carpometacarpal 
CTS  carpal tunnel syndrome
DM  diabetes mellitus
EDB  extensor digitorum brevis
EEC  El Escorial criteria
EMG  electromyography
FMF  fine motor function
FP  fasciculation potential
GBS  Guillain-Barré syndrome
HDsEMG  high-density surface electromyography
IBM  inclusion body myositis
IED     inter-electrode distance
IQR  interquartile range
ISI  interspike interval
IVIg  intravenous immunoglobulin
I/V  current-threshold 
LMN  lower motor neuron
MCP  metacarpophalangeal
MD  multiplet discharge
MMN  multifocal motor neuropathy
MND  motor neuron disease
MRI       magnetic resonance imaging 
MU  motor unit
MUAP  motor unit action potential
MUNE  motor unit number estimation
MVC  maximum voluntary contraction
NCS  nerve conduction studies
NCV  motor nerve conduction velocity
NRMSE  normalized root mean square error
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PCB  printed circuit board
PLS  primary lateral sclerosis 
PMA  progressive muscular atrophy
PPV     positive predictive value
PSW  positive sharp waves 
ROC  receiver operating characteristic
SD  standard deviation
SDTC  strength duration time constant
SEM  standard error of the mean
sEMG    surface electromyography
SI  stimulus intensity
SMA  spinal muscular atrophy
TE  threshold electrotonus
TEd  depolarizing threshold electrotonus
TEh  hyperpolarizing threshold electrotonus
UMN  upper motor neuron
VC  vital capacity
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Dankwoord
Nu is het dan zover dat ik aan mijn dankwoord kan beginnen. Dat betekent dat mijn promotie er 
bijna op zit. In het begin van mijn onderzoek, als er door mijn omgeving gevraagd werd waarnaar 
ik onderzoek deed en ik daarbij de zenuwaandoening ALS liet vallen, bleef het rinkelen van het 
spreekwoordelijke belletje vaak achterwege. Daarin is vooral afgelopen jaar veel veranderd door de 
wereldwijde hype met de Ice Bucket Challenge. In dit gedeelte van mijn proefschrift wil ik graag 
terugblikken op de afgelopen jaren en vooral stilstaan bij de mensen die direct en indirect betrokken 
zijn geweest bij mijn promotieonderzoek. 
Beste promotor, beste Pieter, vanaf het begin van mijn project heb je me gesteund. Ook na het vertrek 
van zowel Joleen als Gerhard ben je blijven vertrouwen in een succesvolle afronding. Het laatste 
jaar heb je zonder problemen min of meer de rol van directe begeleider overgenomen, ondanks je 
drukke agenda. Dankzij jou heb ik een blik kunnen werpen in het werk van een neuroloog. Bij onze 
afspraken nam je de tijd om mij te dwingen helder, kort en bondig te verwoorden wat daadwerkelijk 
belangrijk is in de klinische praktijk door het stellen van de juiste en kritische vragen. Bij jou geldt 
afspraak is afspraak en dat is erg veel waard. Ik waardeer het zeer dat je me ook bij andere zaken 
hebt betrokken, zoals de neuro-immunologiebijeenkomsten op de woensdagmiddag en de vele 
neurologie-activiteiten. Hierin ben je in staat om de juiste balans en sfeer te creëren tussen plezier 
hebben en hoogwaardig onderzoek doen. Naast dit proefschrift, heeft dit geresulteerd in onze eigen 
Ice Bucket Challenge. We zitten nog steeds te wachten op de video van de uitgedaagden. Dank voor 
je begeleiding en de ruimte die ik gekregen heb om mijn onderzoek af te ronden. 
Beste copromotoren, beste Joleen en Gerhard, bij mijn sollicitatiegesprek met jullie eind 2009 
kwam ik in eerste instantie voor een andere functie, maar ik liep anderhalf uur later naar buiten 
met een promotieonderzoek. Bij de KNF waren jullie de drijvende kracht achter veel lopende 
onderzoeksprojecten naast dat van mij. Daarom was het ook een enorme aderlating toen jullie na 
1,5 jaar van mijn promotieonderzoek relatief kort na elkaar aangaven te vertrekken bij de KNF. Hierna 
was het niet alleen voor mij, maar ook voor jullie, zoeken naar de juiste balans om het project tot 
een goed einde te brengen. Dat was niet altijd even gemakkelijk, maar nu ik het dankwoord kan 
schrijven, betekent dat dus dat het is gelukt! Joleen, jij bent als geen ander in staat om zowel de meest 
ingewikkelde details als de grote lijnen binnen enkele minuten helder en overtuigend te verwoorden 
en tevens duidelijk op papier over te brengen. Na je vertrek is Rotterdam – Delft dan ook bij mijn vaste 
routes gaan horen. Dank voor de vele waardevolle commentaren op mijn artikelen en je begeleiding 
tijdens het project. Gerhard, na je vertrek is ook Rotterdam – Heemstede een bekende route voor 
me geworden. In onze besprekingen kon je altijd duidelijk mijn onderzoek en resultaten in het KNF-
perspectief zetten en vanuit dat oogpunt aangeven welke elementen belangrijk waren. Ik wil je dan 
ook bedanken voor je begeleiding. 
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Graag wil ik hierbij ook de leden van de kleine commissie, prof.dr. P.A.E. Sillevis Smitt, prof.dr.ir. D.F. 
Stegeman en dr. H. Franssen, bedanken voor het beoordelen van het manuscript. Prof. Sillevis 
Smitt, bedankt dat u de tijd wilde nemen om het manuscript te beoordelen tussen uw drukke 
werkzaamheden door. Prof. Stegeman, dank voor uw waardevolle suggesties om het manuscript te 
verbeteren. Dr. Franssen, dank voor uw hulp bij de interpretatie van enkele meetresultaten tijdens 
mijn promotieonderzoek. De overige leden van de commissie, prof.dr. H.J. Stam en prof.dr. H.C.W. 
Beijerinck wil ik bedanken voor hun bereidheid om zitting te nemen in de promotiecommissie. Prof. 
Beijerinck, dank dat u op deze manier bij de afsluiting van mijn promotietraject wilt zijn, nadat ik via u 
ook in Rotterdam terechtgekomen ben. 
Beste Inger, uiteindelijk ben je relatief kort bij de KNF geweest, mede door je zwangerschap, maar ook 
omdat je hart uiteindelijk toch meer ergens anders lag. Ondanks dat, was je bij bijna alle studies van 
mijn promotieonderzoek betrokken. Dank voor de vele tips voor het schrijven van artikelen en het 
regelen van de zaken rondom mijn promotie. 
Beste Ellen en Judith, bij de start van mijn project waren jullie de andere twee promotieonderzoekers 
bij de KNF. Dank voor het wegwijs maken in de wereld van de EMG-onderzoekstechnieken. Ellen, 
jouw onderzoek heb ik voortgezet. Ondertussen ben je moeder geworden en begonnen met de 
huisartsenopleiding. Judith, jij bent nu neuroloog op de afdeling. Bij jou kan ik altijd terecht voor 
waardevolle discussies over de mogelijke klinische toepassingen van ons onderzoek. Alle twee veel 
succes met de afronding van jullie promotie!
Dear Ivan, thank you for our research related discussions in Leuven. Within a few weeks, we finished 
our “Como” paper. Eventually, this cooperation resulted in a second paper as well. I will never forget 
our trip to Milan and Como. I had a great time, so I hope we keep in touch!
Beste Joseph, ik waardeer het zeer dat je ruim de tijd nam om te discussiëren over mijn resultaten en 
mijn artikelen te bekijken in de laatste maanden van mijn promotie. Het was niet ongewoon dat ik na 
een gesprek met jou naar buiten liep met relevante wetenschappelijke artikelen in mijn Inbox. Daarbij 
was je altijd oprecht geïnteresseerd in hoe mijn bevindingen van nut konden zijn in de praktijk. 
Erg veel praktische zaken tijdens mijn promotieproject zijn een stuk gemakkelijker verlopen dankzij 
Monique en Jacqueline. Dank voor het werk dat jullie mij uit handen hebben genomen, de tijd die 
jullie namen voor een praatje en de gezelligheid die jullie meebrachten! 
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Tijdens de periode waarin de patiënten bij mij langskwamen had ik regelmatig contact met Cisca. Jij 
bent degene die de patiënten opvangt als ze het vreselijke nieuws hebben gehoord. In dit moeilijke 
proces ben jij een steun voor hen. Ik vind het bewonderenswaardig met hoeveel toewijding je dit 
doet. Het was een plezier om met je samen te werken! Hier wil ik dan ook de patiënten bedanken voor 
hun deelname aan mijn onderzoek. Hun persoonlijke situaties hebben veel indruk op mij gemaakt. 
Verder zijn er nog een aantal personen die ik wil bedanken. Marjan, dank voor de attentie na het 
winnen van mijn prijs in Amerika, ondanks alle drukte in de kliniek. De samenwerking met het KNF-
secretariaat was onmisbaar bij de zaken rondom de metingen, dank daarvoor! Verder wil ik alle KNF-
laboranten bedanken voor de fijne tijd op de afdeling en de AIOS Neurologie die de afgelopen jaren 
hun stages bij de KNF hebben gedaan. Geert en Marc, bedankt voor de vele wandelingen van en 
naar de koffieautomaat. Geert, in de laatste paar jaar kon ik met jou sparren als ik ergens mee vastliep. 
Jouw nuchtere kijk en droge humor waren hierin zeer verfrissend. Daarnaast wil ik graag ook de 
andere collega-onderzoekers bij de neuro-immunologiebijeenkomsten bedanken! Niet alleen voor 
de nuttige feedback op mijn presentaties, maar ook voor de gezelligheid bij de andere activiteiten!
Anouk, jij was met je keuzeonderzoek bezig bij de KNF toen ik met mijn promotieonderzoek begon. 
Daarna hebben we contact gehouden en inmiddels ben jij ook bijna klaar met je promotieonderzoek. 
De afgelopen jaren hebben we regelmatig samen koffiepauzes gehad, waarin we met veel plezier het 
lief en leed van het doen van promotieonderzoek met elkaar deelden. Succes met de afronding van 
jouw promotie!
Gedurende mijn project zijn er meer medewerkers bij de KNF en Neurologie, en collega-onderzoekers 
in meer of mindere mate bij mijn promotie betrokken geweest. Ik kan jullie hier niet allemaal noemen, 
want dan ga ik zeker namen vergeten. Allemaal bedankt voor de mooie tijd! 
Dan zijn er nog veel mensen buiten mijn werk om die voor een onvergetelijke tijd hebben gezorgd 
tijdens mijn promotie. Familie, vrienden en kennissen waarmee ik de afgelopen jaren opgetrokken 
heb. Oud-studiegenoten van BMT, mede-“topsporters” van het schaatsen, tennissen en hardlopen uit 
Rotterdam en de regio Eindhoven. Bernard, je was altijd belangstellend over de vorderingen van mijn 
promotieonderzoek. Succes met het afronden van je coschappen! Frederieke, dank voor de steun, 
het doorlezen van de teksten en het letten op de taalkundige formuleringen. Je was echt betrokken 
bij de laatste loodjes van mijn proefschrift. Myron en Joost, bedankt voor de vele mooie stapavonden 
in Rotterdam en avontuurlijke vakanties. Verder ook mijn improvisatiegroepje, we vormen een mooi, 
chaotisch stelletje bij elkaar. Het was heerlijk om na een dag werken plots midden in een ruimtereis te 
zitten, een giraffe met hoogtevrees te hebben verkocht en panda’s voorbij te zien vliegen. 
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Paul en Ot, ik ben zeer vereerd dat jullie mijn paranimfen willen zijn. Ot, na onze studie BMT in 
Eindhoven hebben we altijd contact gehouden. Door mijn verhuizing naar Rotterdam, de afronding 
van jouw promotie en je nieuwe baan, hebben we elkaar de laatste jaren minder vaak gezien. Ondanks 
dat hielden we elkaar op de hoogte van de belangrijke zaken in het leven. Paul en Samantha, bij jullie 
staat de deur altijd voor mij open, dank daarvoor. Paul, de beste besprekingen waren misschien wel 
onze wekelijkse “meetings” op de dinsdagavond in Rotterdam of Den Haag. We kunnen lachen om 
de meest onzinnige dingen, praten over de meest serieuze zaken in het leven, inhoudelijk discussies 
voeren over ons werk en werkelijk alles daar tussenin. Het feit dat we daar zo gemakkelijk tussen 
kunnen switchen is bijzonder. Ik hoop onze “meetings” nog lang voort te kunnen zetten. 
Pap en mam, jullie staan altijd voor mij klaar. Dank voor jullie onvoorwaardelijke steun. Ik kan hierover 
nog heel veel zeggen, maar voor jullie is dat nu juist niet nodig. Elisabeth, lieve zus, helaas ben je hier 
niet meer bij. Wat zou je trots zijn geweest! 
Boudewijn Sleutjes
Rotterdam, maart 2015
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Boudewijn Sleutjes werd geboren op 2 juni 1983 te Boxtel. In 2001 behaalde hij zijn Gymnasium 
diploma aan het Jacob-Roelandslyceum te Boxtel. Aansluitend studeerde hij Biomedische Technologie 
aan de Technische Universiteit Eindhoven. Deze studie sloot hij met grote waardering af in 2007. Zijn 
afstudeerwerk deed hij op de afdeling Klinische Fysica en Sportgeneeskunde van het Máxima Medisch 
Centrum te Veldhoven. Hierna begon hij met de ontwerpersopleiding “Design and Technology of 
Instrumentation” van het Stan Ackermans Instituut. Als onderdeel van deze ontwerpersopleiding 
werkte hij 1 jaar bij Philips Research in Eindhoven en 4 maanden bij Ballard Power Systems in 
Vancouver, Canada. Deze tweejarige ontwerpersopleiding rondde hij af in december 2009. In maart 
2010 startte hij met zijn promotieonderzoek bij de afdeling Klinische Neurofysiologie en Neurologie 
van het Erasmus MC te Rotterdam, resulterend in dit proefschrift.
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PhD portfolio 
Summary of PhD training and teaching Year Workload (ECTS)
General courses
Structure and organization of the nervous system 2010 3.0
Motor systems 2011 3.0
Neurological disorders 2011 3.0
Biomedical English writing and Communication 2011 3.0
Course for quantitative researchers 2012 3.0
Repeated measurements 2012 1.4
Missing values in clinical research 2012 0.7
International conferences
3rd and 4th Dutch Biomedical Engineering Conference 2011, 2013 2.0
7th International Workshop on Biosignal Interpretation 2012 0.5
59th Annual Meeting of the AANEM 2012 1.0
24th International symposium on ALS/MND 2013 0.5
30th International congress of clinical neurophysiology (ICCN) 2014 0.5
Seminars and workshops
Reanimatie bij volwassenen, basic life support 2012 0.1
Trainingsdag dialoogtraining 2012 0.2
Loopbaanoriëntatie 2012 1.0
PhD day 2010, 2012 0.5
In depth courses
MUNE techniques + MUAP quantitation at AANEM 2012 0.5
Other
Prinses Beatrix Spierfonds, Spierziektecongres 2012 0.5
ALS congres 2010 0.2
Presentaties bij KNF en Neurologie 2012 - 2015 1.0
Presentaties bij neuro-immunologiebijeenkomsten 2011 - 2015 1.0
Wetenschapsmiddag, Erasmus MC 2013 0.1
KNF dagen 2014 1.0
Teaching activities
Supervising medical students 2010 1.5
Teaching of 2nd year master of neuroscience students 2011 - 2013 1.5
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Dinsdag 26 mei 2015 om 13:30 uur
 
in de Prof. dr. Andries Querido zaal 
van het Erasmus MC 
(Eg-370, onderwijscentrum)
 Dr. Molewaterplein 50, Rotterdam
Na afloop van de promotie 
bent u van harte uitgenodigd voor 
de receptie ter plaatse
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